<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39125722</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>15</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>26</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">8155</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms25158155</ELocationID><Abstract><AbstractText>At present, COVID-19 remains a public health concern due to the ongoing evolution of SARS-CoV-2 and its prevalence in particular countries. This paper provides an updated overview of the epidemiology and pathogenesis of COVID-19, with a focus on the emergence of SARS-CoV-2 variants and the phenomenon known as 'long COVID'. Meanwhile, diagnostic and detection advances will be mentioned. Though many inventions have been made to combat the COVID-19 pandemic, some outstanding ones include multiplex RT-PCR, which can be used for accurate diagnosis of SARS-CoV-2 infection. ELISA-based antigen tests also appear to be potential diagnostic tools to be available in the future. This paper also discusses current treatments, vaccination strategies, as well as emerging cell-based therapies for SARS-CoV-2 infection. The ongoing evolution of SARS-CoV-2 underscores the necessity for us to continuously update scientific understanding and treatments for it.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Yiu-Sing</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Applied Biology &amp; Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Ching-Yin</ForeName><Initials>CY</Initials><Identifier Source="ORCID">0009-0002-2233-0222</Identifier><AffiliationInfo><Affiliation>Department of Applied Biology &amp; Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Pak-Hei</ForeName><Initials>PH</Initials><AffiliationInfo><Affiliation>Department of Applied Biology &amp; Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsang</LastName><ForeName>Hin-Fung</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Department of Applied Biology &amp; Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Sze-Chuen Cesar</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Applied Biology &amp; Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">endemic</Keyword><Keyword MajorTopicYN="N">post-pandemic</Keyword><Keyword MajorTopicYN="N">review</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>10</Day><Hour>15</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>10</Day><Hour>15</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>10</Day><Hour>1</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>7</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39125722</ArticleId><ArticleId IdType="pmc">PMC11312261</ArticleId><ArticleId IdType="doi">10.3390/ijms25158155</ArticleId><ArticleId IdType="pii">ijms25158155</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention  CDC COVID Data Tracker. [Online]. Centers for Disease Control and Prevention.  [(accessed on 26 June 2024)];2024  Available online:  https://covid.cdc.gov/covid-data-tracker/#variant-proportions.</Citation></Reference><Reference><Citation>Tsang H.F., Chan L.W.C., Cho W.C.S., Yu A.C.S., Yim A.K.Y., Chan A.K.C., Ng L.P.W., Wong Y.K.E., Pei X.M., Li M.J.W., et al. An update on COVID-19 pandemic: The epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev. Anti-Infect. Ther. 2020;19:877&#x2013;888. doi: 10.1080/14787210.2021.1863146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2021.1863146</ArticleId><ArticleId IdType="pubmed">33306423</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui J., Li F., Shi Z.-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019;17:181&#x2013;192. doi: 10.1038/s41579-018-0118-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0118-9</ArticleId><ArticleId IdType="pmc">PMC7097006</ArticleId><ArticleId IdType="pubmed">30531947</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo P.C.Y., Lau S.K.P., Huang Y., Yuen K.-Y. Coronavirus Diversity, Phylogeny and Interspecies Jumping. Exp. Biol. Med. 2009;234:1117&#x2013;1127. doi: 10.3181/0903-MR-94.</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/0903-MR-94</ArticleId><ArticleId IdType="pubmed">19546349</ArticleId></ArticleIdList></Reference><Reference><Citation>Myint S.H. The Coronaviridae. Plenum Press; New York, NY, USA: 1995. Human coronavirus infections; pp. 389&#x2013;401.</Citation></Reference><Reference><Citation>Vabret A., Mourez T., Dina J., Van Der Hoek L., Gouarin S., Petitjean J., Brouard J., Freymuth F. Human coronavirus NL63, France. Emerg. Infect. Dis. 2005;11:1225&#x2013;1229. doi: 10.3201/eid1108.050110.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid1108.050110</ArticleId><ArticleId IdType="pmc">PMC3320486</ArticleId><ArticleId IdType="pubmed">16102311</ArticleId></ArticleIdList></Reference><Reference><Citation>Woo P.C.Y., Lau S.K.P., Chu C.-M., Chan K.-H., Tsoi H.-W., Huang Y., Wong B.H.L., Poon R.W.S., Cai J.J., Luk W.-K., et al. Characterization and Complete Genome Sequence of a Novel Coronavirus, Coronavirus HKU1, from Patients with Pneumonia. J. Virol. 2005;79:884&#x2013;895. doi: 10.1128/JVI.79.2.884-895.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.79.2.884-895.2005</ArticleId><ArticleId IdType="pmc">PMC538593</ArticleId><ArticleId IdType="pubmed">15613317</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogimi C., Kim Y.J., Martin E.T., Huh H.J., Chiu C.H., Englund J.A. What&#x2019;s new with the old coronaviruses? J. Pediatr. Infect. Dis. Soc. 2020;9:210&#x2013;217. doi: 10.1093/jpids/piaa037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jpids/piaa037</ArticleId><ArticleId IdType="pmc">PMC7188130</ArticleId><ArticleId IdType="pubmed">32314790</ArticleId></ArticleIdList></Reference><Reference><Citation>De Groot R.J., Baker S.C., Baric R.S., Brown C.S., Drosten C., Enjuanes L., Fouchier R.A., Galiano M., Gorbalenya A.E., Memish Z.A., et al. Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group. J. Virol. 2013;87:7790&#x2013;7792. doi: 10.1128/JVI.01244-13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01244-13</ArticleId><ArticleId IdType="pmc">PMC3700179</ArticleId><ArticleId IdType="pubmed">23678167</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiris J.S.M., Lai S.T., Poon L.L.M., Guan Y., Yam L.Y.C., Lim W., Nicholls J., Yee W.K.S., Yan W.W., Cheung M.T., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319&#x2013;1325. doi: 10.1016/S0140-6736(03)13077-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)13077-2</ArticleId><ArticleId IdType="pmc">PMC7112372</ArticleId><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo G., Gao S.-J. Global health concerns stirred by emerging viral infections. J. Med. Virol. 2020;92:399&#x2013;400. doi: 10.1002/jmv.25683.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25683</ArticleId><ArticleId IdType="pmc">PMC7166855</ArticleId><ArticleId IdType="pubmed">31967329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig S., Zarbock A. Coronaviruses and SARS-CoV-2: A Brief Overview. Anesth. Analg. 2020;131:93&#x2013;96. doi: 10.1213/ANE.0000000000004845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0000000000004845</ArticleId><ArticleId IdType="pmc">PMC7173023</ArticleId><ArticleId IdType="pubmed">32243297</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5:536&#x2013;544. doi: 10.1038/s41564-020-0695-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0695-z</ArticleId><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>Fouchier R.A., Kuiken T., Schutten M., Van Amerongen G., Van Doornum G.J., Van Den Hoogen B.G., Peiris M., Lim W., St&#xf6;hr K., Osterhaus A.D. Koch&#x2019;s postulates fulfilled for SARS virus. Nature. 2003;423:240. doi: 10.1038/423240a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/423240a</ArticleId><ArticleId IdType="pmc">PMC7095368</ArticleId><ArticleId IdType="pubmed">12748632</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKenzie J.S., Smith D.W. COVID-19: A novel zoonotic disease caused by a coronavirus from China: What we know and what we don&#x2019;t. Microbiol. Aust. 2020;41:45. doi: 10.1071/MA20013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1071/MA20013</ArticleId><ArticleId IdType="pmc">PMC7086482</ArticleId><ArticleId IdType="pubmed">32226946</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu H., Stratton C.W., Tang Y.-W. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J. Med. Virol. 2020;92:401&#x2013;402. doi: 10.1002/jmv.25678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25678</ArticleId><ArticleId IdType="pmc">PMC7166628</ArticleId><ArticleId IdType="pubmed">31950516</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak&#x2013;an update on the status. Mil. Med. Res. 2020;7:11. doi: 10.1186/s40779-020-00240-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40779-020-00240-0</ArticleId><ArticleId IdType="pmc">PMC7068984</ArticleId><ArticleId IdType="pubmed">32169119</ArticleId></ArticleIdList></Reference><Reference><Citation>Horton R. Offline: 2019-nCoV outbreak-early lessons. Lancet. 2020;395:322. doi: 10.1016/S0140-6736(20)30212-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30212-9</ArticleId><ArticleId IdType="pmc">PMC7137834</ArticleId><ArticleId IdType="pubmed">32007152</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Why Is COVID-19 Data Being Presented as Weekly Statistics? [Online]. World Health Organization. 2024.  [(accessed on 13 April 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases?m49=156&amp;n=c.</Citation></Reference><Reference><Citation>Belser J.A., Rota P.A., Tumpey T.M. Ocular tropism of respiratory viruses. Microbiol. Mol. Biol. Rev. 2013;77:144&#x2013;156. doi: 10.1128/MMBR.00058-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MMBR.00058-12</ArticleId><ArticleId IdType="pmc">PMC3591987</ArticleId><ArticleId IdType="pubmed">23471620</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu Q., Shi Y. Coronavirus disease (COVID-19) and neonate: What neonatologist need to know. J. Med. Virol. 2020;92:564&#x2013;567. doi: 10.1002/jmv.25740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25740</ArticleId><ArticleId IdType="pmc">PMC7228398</ArticleId><ArticleId IdType="pubmed">32115733</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H., Leong F.Y., Xu G., Kang C.W., Lim K.H., Tan B.H., Loo C.M. Airborne dispersion of droplets during coughing: A physical model of viral transmission. Sci. Rep. 2021;11:4617. doi: 10.1038/s41598-021-84245-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84245-2</ArticleId><ArticleId IdType="pmc">PMC7907382</ArticleId><ArticleId IdType="pubmed">33633316</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang F., Deng L., Zhang L., Cai Y., Cheung C.W., Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19) J. Gen. Intern. Med. 2020;35:1545&#x2013;1549. doi: 10.1007/s11606-020-05762-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-020-05762-w</ArticleId><ArticleId IdType="pmc">PMC7088708</ArticleId><ArticleId IdType="pubmed">32133578</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T. Fomites and the COVID-19 Pandemic: An Evidence Review on Its Role in Viral Transmission. National Collaborating Centre for Environmental Health; Vancouver, BC, Canada: 2021. pp. 1&#x2013;24.</Citation></Reference><Reference><Citation>Wu D., Wu T., Liu Q., Yang Z. The SARS-CoV-2 outbreak: What we know. Int. J. Infect. Dis. 2020;94:44&#x2013;48. doi: 10.1016/j.ijid.2020.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.03.004</ArticleId><ArticleId IdType="pmc">PMC7102543</ArticleId><ArticleId IdType="pubmed">32171952</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Doremalen N., Bushmaker T., Morris D.H., Holbrook M.G., Gamble A., Williamson B.N., Tamin A., Harcourt J.L., Thornburg N.J., Gerber S.I., et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N. Engl. J. Med. 2020;382:1564&#x2013;1567. doi: 10.1056/NEJMc2004973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2004973</ArticleId><ArticleId IdType="pmc">PMC7121658</ArticleId><ArticleId IdType="pubmed">32182409</ArticleId></ArticleIdList></Reference><Reference><Citation>Koenig K.L., Bey C.K., McDonald E.C. 2019-nCoV: The identify-isolate-inform (3I) tool applied to a novel emerging coronavirus. West. J. Emerg. Med. 2020;21:184&#x2013;190. doi: 10.5811/westjem.2020.1.46760.</Citation><ArticleIdList><ArticleId IdType="doi">10.5811/westjem.2020.1.46760</ArticleId><ArticleId IdType="pmc">PMC7081861</ArticleId><ArticleId IdType="pubmed">32191174</ArticleId></ArticleIdList></Reference><Reference><Citation>Tellier R. COVID-19: The case for aerosol transmission. Interface Focus. 2022;12:20210072. doi: 10.1098/rsfs.2021.0072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsfs.2021.0072</ArticleId><ArticleId IdType="pmc">PMC8831082</ArticleId><ArticleId IdType="pubmed">35261731</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou C. Evaluating new evidence in the early dynamics of the novel coronavirus COVID-19 outbreak in Wuhan, China with real time domestic traffic and potential asymptomatic transmissions. MedRxiv. 2020 doi: 10.1101/2020.02.15.20023440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.02.15.20023440</ArticleId></ArticleIdList></Reference><Reference><Citation>Morawska L.J.G.R., Johnson G.R., Ristovski Z.D., Hargreaves M., Mengersen K., Corbett S., Chao C.Y.H., Li Y., Katoshevski D. Size distribution and sites of origin of droplets expelled from the human respiratory tract during expiratory activities. J. Aerosol Sci. 2009;40:256&#x2013;269. doi: 10.1016/j.jaerosci.2008.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaerosci.2008.11.002</ArticleId><ArticleId IdType="pmc">PMC7126899</ArticleId><ArticleId IdType="pubmed">32287373</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortellessa G., Stabile L., Arpino F., Faleiros D.E., Van Den Bos W., Morawska L., Buonanno G. Close proximity risk assessment for SARS-CoV-2 infection. Sci. Total Environ. 2021;794:148749. doi: 10.1016/j.scitotenv.2021.148749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scitotenv.2021.148749</ArticleId><ArticleId IdType="pmc">PMC8242194</ArticleId><ArticleId IdType="pubmed">34225157</ArticleId></ArticleIdList></Reference><Reference><Citation>Denison M.R., Graham R.L., Donaldson E.F., Eckerle L.D., Baric R.S. Coronaviruses: An RNA proofreading machine regulates replication fidelity and diversity. RNA Biol. 2011;8:270&#x2013;279. doi: 10.4161/rna.8.2.15013.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/rna.8.2.15013</ArticleId><ArticleId IdType="pmc">PMC3127101</ArticleId><ArticleId IdType="pubmed">21593585</ArticleId></ArticleIdList></Reference><Reference><Citation>Mlcochova P., Kemp S., Dhar M.S., Papa G., Meng B., Mishra S., Whittaker C., Mellan T., Ferreira I., Datir R., et al. SARS-CoV-2 B. 1.617. 2 Delta variant emergence, replication and sensitivity to neutralising antibodies. BioRxiv. 2021 doi: 10.1101/2021.05.08.443253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.05.08.443253</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandeel M., Mohamed M.E.M., Abd El-Lateef H.M.A., Venugopala K.N., El-Beltagi H.S. Omicron variant genome evolution and phylogenetics. J. Med. Virol. 2022;94:1627&#x2013;1632. doi: 10.1002/jmv.27515.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27515</ArticleId><ArticleId IdType="pmc">PMC9015349</ArticleId><ArticleId IdType="pubmed">34888894</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Staropoli I., Michel V., Lemoine F., Donati F., Prot M., Porrot F., Guivel-Benhassine F., Jeyarajah B., Brisebarre A., et al. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion. Nat. Commun. 2024;15:2254. doi: 10.1038/s41467-024-46490-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-46490-7</ArticleId><ArticleId IdType="pmc">PMC10938001</ArticleId><ArticleId IdType="pubmed">38480689</ArticleId></ArticleIdList></Reference><Reference><Citation>Stehlik P., Dowsett C., Camacho X., Falster M.O., Lim R., Nasreen S., Pratt N.L., Pearson S.A., Henry D. Evolution of the data and methods in real-world COVID-19 vaccine effectiveness studies on mortality: A scoping review protocol. BMJ Open. 2024;14:e079071. doi: 10.1136/bmjopen-2023-079071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2023-079071</ArticleId><ArticleId IdType="pmc">PMC10952922</ArticleId><ArticleId IdType="pubmed">38508618</ArticleId></ArticleIdList></Reference><Reference><Citation>Haider N., Hasan M.N., Guitian J., Khan R.A., McCoy D., Ntoumi F., Dar O., Ansumana R., Uddin J., Zumla A., et al. The disproportionate case-fatality ratio of COVID-19 between countries with the highest vaccination rates and the rest of the world. IJID Reg. 2023;6:159&#x2013;166. doi: 10.1016/j.ijregi.2023.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijregi.2023.01.011</ArticleId><ArticleId IdType="pmc">PMC9881127</ArticleId><ArticleId IdType="pubmed">36721772</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Statement on the Fifteenth Meeting of the IHR (2005) Emergency Committee on the COVID-19 Pandemic. [Online]. World Health Organization. 2023.  [(accessed on 26 June 2024)].  Available online:  https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic.</Citation></Reference><Reference><Citation>World Health Organization  Statement on the Update of Who&#x2019;s Working Definitions and Tracking System for SARS-COV-2 Variants of Concern and Variants of Interest. [Online]. World Health Organization. 2023.  [(accessed on 26 June 2024)].  Available online:  https://www.who.int/news/item/16-03-2023-statement-on-the-update-of-who-s-working-definitions-and-tracking-system-for-sars-cov-2-variants-of-concern-and-variants-of-interest.</Citation></Reference><Reference><Citation>Rodriguez H., Hartert T.V., Gebretsadik T., Carroll K.N., Larkin E.K. A simple respiratory severity score that may be used in evaluation of acute respiratory infection. BMC Res. Notes. 2016;9:1&#x2013;4. doi: 10.1186/s13104-016-1899-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-016-1899-4</ArticleId><ArticleId IdType="pmc">PMC4751705</ArticleId><ArticleId IdType="pubmed">26868120</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku Y., Yo M.S., Tolentino J.E., Uriu K., Okumura K., Ito J., Sato K. Virological characteristics of the SARS-CoV-2 KP. 3, LB. 1, and KP. 2.3 variants. Lancet Infect. Dis. 2024 doi: 10.1016/S1473-3099(24)00415-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00415-8</ArticleId><ArticleId IdType="pubmed">38945150</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Coronavirus Disease (COVID-19) Situation Reports. [Online]. World Health Organization. 2024.  [(accessed on 26 June 2024)].  Available online:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.</Citation></Reference><Reference><Citation>World Health Organization  COVID-19 Deaths WHO COVID-19 Dashboard. [Online]. World Health Organization. 2024.  [(accessed on 27 June 2024)].  Available online:  https://data.who.int/dashboards/covid19/deaths.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Vaccination Trends-Adults. [Online]. Centers for Disease Control and Prevention.  [(accessed on 28 June 2024)];2024  Available online:  https://www.cdc.gov/respiratory-viruses/data-research/dashboard/vaccination-trends-adults.html.</Citation></Reference><Reference><Citation>European Centre for Disease Prevention and Control  Interim COVID-19 Vaccination Coverage in the EU/EEA during the 2023&#x2013;2024 Season Campaigns 2024. [Online]. European Centre for Disease Prevention and Control.  [(accessed on 28 June 2024)].  Available online:  https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-vaccination-coverage-2023%E2%80%9324.pdf.</Citation></Reference><Reference><Citation>World Health Organization  COVID-19 Cases WHO COVID-19 Dashboard. [Online]. World Health Organization. 2024.  [(accessed on 26 June 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases?m49=620&amp;n=o.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  COVID-19 Wastewater Data&#x2014;National Trends. Centers for Disease Control and Prevention.  [(accessed on 26 June 2024)];2024  Available online:  https://www.cdc.gov/nwss/rv/COVID19-nationaltrend.html.</Citation></Reference><Reference><Citation>Pulliam J.R., van Schalkwyk C., Govender N., von Gottberg A., Cohen C., Groome M.J., Dushoff J., Mlisana K., Moultrie H. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa. Science. 2022;376:eabn4947. doi: 10.1126/science.abn4947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn4947</ArticleId><ArticleId IdType="pmc">PMC8995029</ArticleId><ArticleId IdType="pubmed">35289632</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Zhu W., Han X., Chen M., Li X., Huang H., Zhang M., Wei R., Zhang H., Yang C., et al. How does the SARS-CoV-2 reinfection rate change over time? The global evidence from systematic review and meta-analysis. BMC Infect. Dis. 2024;24:339. doi: 10.1186/s12879-024-09225-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-024-09225-z</ArticleId><ArticleId IdType="pmc">PMC10956270</ArticleId><ArticleId IdType="pubmed">38515023</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes A.R., Oliveira M.S., Tavares B.M., Luna-Muschi A., Lazari C.d.S., Montal A.C., de Faria E., Maia F.L., Barboza A.d.S., Leme M.D., et al. Reinfection rate in a cohort of healthcare workers over 2 years of the COVID-19 pandemic. Sci. Rep. 2023;13:712. doi: 10.1038/s41598-022-25908-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-25908-6</ArticleId><ArticleId IdType="pmc">PMC9837751</ArticleId><ArticleId IdType="pubmed">36639411</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health  COVID-19 Reinfection Data. [Online]. Department of Health.  [(accessed on 26 June 2024)];2023  Available online:  https://coronavirus.health.ny.gov/covid-19-reinfection-data.</Citation></Reference><Reference><Citation>Wei J., Stoesser N., Matthews P.C., Khera T., Gethings O., Diamond I., Studley R., Taylor N., Peto T.E., Walker A.S., et al. Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population. Nat. Commun. 2024;15:1008. doi: 10.1038/s41467-024-44973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-44973-1</ArticleId><ArticleId IdType="pmc">PMC10837445</ArticleId><ArticleId IdType="pubmed">38307854</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoeggerl A.D., Nunhofer V., Weidner L., Lauth W., Zimmermann G., Badstuber N., Grabmer C., Kartal O., Jungbauer C., Neureiter H., et al. Dissecting the dynamics of SARS-CoV-2 reinfections in blood donors with pauci-or asymptomatic COVID-19 disease course at initial infection. Infect. Dis. 2024:1&#x2013;11. doi: 10.1080/23744235.2024.2367112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2024.2367112</ArticleId><ArticleId IdType="pubmed">38869944</ArticleId></ArticleIdList></Reference><Reference><Citation>de Anda-J&#xe1;uregui G., G&#xf3;mez-Romero L., Ca&#xf1;as S., Campos-Romero A., Alc&#xe1;ntar-Fern&#xe1;ndez J., Cedro-Tanda A. COVID-19 reinfections in Mexico City: Implications for public health. Front. Public Health. 2024;11:1321283. doi: 10.3389/fpubh.2023.1321283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1321283</ArticleId><ArticleId IdType="pmc">PMC10899476</ArticleId><ArticleId IdType="pubmed">38419814</ArticleId></ArticleIdList></Reference><Reference><Citation>Antia R., Halloran M.E. Transition to endemicity: Understanding COVID-19. Immunity. 2021;54:2172&#x2013;2176. doi: 10.1016/j.immuni.2021.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.09.019</ArticleId><ArticleId IdType="pmc">PMC8461290</ArticleId><ArticleId IdType="pubmed">34626549</ArticleId></ArticleIdList></Reference><Reference><Citation>Akkiz H. Implications of the novel mutations in the SARS-CoV-2 genome for transmission, disease severity, and the vaccine development. Front. Med. 2021;8:636532. doi: 10.3389/fmed.2021.636532.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.636532</ArticleId><ArticleId IdType="pmc">PMC8137987</ArticleId><ArticleId IdType="pubmed">34026780</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen K.G., Rambaut A., Lipkin W.I., Holmes E.C., Garry R.F. The proximal origin of SARS-CoV-2. Nat. Med. 2020;26:450&#x2013;452. doi: 10.1038/s41591-020-0820-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0820-9</ArticleId><ArticleId IdType="pmc">PMC7095063</ArticleId><ArticleId IdType="pubmed">32284615</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang S., Hillyer C., Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 2020;41:355&#x2013;359. doi: 10.1016/j.it.2020.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2020.03.007</ArticleId><ArticleId IdType="pmc">PMC7129017</ArticleId><ArticleId IdType="pubmed">32249063</ArticleId></ArticleIdList></Reference><Reference><Citation>V&#x2019;kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155&#x2013;170. doi: 10.1038/s41579-020-00468-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuentes-prior P. Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection. J. Biol. Chem. 2021;296:100135. doi: 10.1074/jbc.REV120.015980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.REV120.015980</ArticleId><ArticleId IdType="pmc">PMC7834812</ArticleId><ArticleId IdType="pubmed">33268377</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Deng W., Li S., Yang X. Advances in research on ACE2 as a receptor for 2019-nCoV. Cell. Mol. Life Sci. 2020;78:531&#x2013;544. doi: 10.1007/s00018-020-03611-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-020-03611-x</ArticleId><ArticleId IdType="pmc">PMC7417784</ArticleId><ArticleId IdType="pubmed">32780149</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanff T.C., Harhay M.O., Brown T.S., Cohen J.B., Mohareb A.M. Is there an association between COVID-19 mortality and the renin-angiotensin system? A call for epidemiologic investigations. Clin. Infect. Dis. 2020;71:870&#x2013;874. doi: 10.1093/cid/ciaa329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa329</ArticleId><ArticleId IdType="pmc">PMC7184340</ArticleId><ArticleId IdType="pubmed">32215613</ArticleId></ArticleIdList></Reference><Reference><Citation>Shieh W.-J., Hsiao C.-H., Paddock C.D., Guarner J., Goldsmith C.S., Tatti K., Packard M., Mueller L., Wu M.-Z., Rollin P., et al. Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan. Hum. Pathol. 2005;36:303&#x2013;309. doi: 10.1016/j.humpath.2004.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humpath.2004.11.006</ArticleId><ArticleId IdType="pmc">PMC7112064</ArticleId><ArticleId IdType="pubmed">15791576</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Zhou Y., Wang D.W. SARS-CoV-2: A potential novel etiology of fulminant myocarditis. Herz. 2020;45:230&#x2013;232. doi: 10.1007/s00059-020-04909-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00059-020-04909-z</ArticleId><ArticleId IdType="pmc">PMC7080076</ArticleId><ArticleId IdType="pubmed">32140732</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Wu M. Pattern recognition receptors in health and diseases. Signal Transduct. Target. Ther. 2021;6:291. doi: 10.1038/s41392-021-00687-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00687-0</ArticleId><ArticleId IdType="pmc">PMC8333067</ArticleId><ArticleId IdType="pubmed">34344870</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebbole D.J. Magnaporthe as a model for understanding host-pathogen interactions. Annu. Rev. Phytopathol. 2007;45:437&#x2013;456. doi: 10.1146/annurev.phyto.45.062806.094346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.phyto.45.062806.094346</ArticleId><ArticleId IdType="pubmed">17489691</ArticleId></ArticleIdList></Reference><Reference><Citation>Streicher F., Jouvenet N. Stimulation of innate immunity by host and viral RNAs. Trends Immunol. 2019;40:1134&#x2013;1148. doi: 10.1016/j.it.2019.10.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2019.10.009</ArticleId><ArticleId IdType="pubmed">31735513</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014;14:36&#x2013;49. doi: 10.1038/nri3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3581</ArticleId><ArticleId IdType="pmc">PMC4084561</ArticleId><ArticleId IdType="pubmed">24362405</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X., Hackbart M., Mettelman R.C., O&#x2019;brien A., Mielech A.M., Yi G., Kao C.C., Baker S.C. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. Proc. Natl. Acad. Sci. USA. 2017;114:E4251&#x2013;E4260. doi: 10.1073/pnas.1618310114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1618310114</ArticleId><ArticleId IdType="pmc">PMC5448190</ArticleId><ArticleId IdType="pubmed">28484023</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., Zhao B., Qu Y., Chen Y., Xiong J., Feng Y., Men D., Huang Q., Liu Y., Yang B., et al. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019. Clin. Infect. Dis. 2020;71:1937&#x2013;1942. doi: 10.1093/cid/ciaa449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa449</ArticleId><ArticleId IdType="pmc">PMC7184354</ArticleId><ArticleId IdType="pubmed">32301997</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul B.D., Lemle M.D., Komaroff A.L., Snyder S.H. Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome. Proc. Natl. Acad. Sci. USA. 2021;118:e2024358118. doi: 10.1073/pnas.2024358118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2024358118</ArticleId><ArticleId IdType="pmc">PMC8403932</ArticleId><ArticleId IdType="pubmed">34400495</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R., Perlman S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017;39:529&#x2013;539. doi: 10.1007/s00281-017-0629-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0629-x</ArticleId><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489&#x2013;1501.e15. doi: 10.1016/j.cell.2020.05.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi D., Weng T., Wu J., Dai C., Luo R., Chen K., Zhu M., Lu X., Cheng L., Chen Q., et al. Dynamic characteristic analysis of antibodies in patients with COVID-19: A 13-month study. Front. Immunol. 2021;12:708184. doi: 10.3389/fimmu.2021.708184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.708184</ArticleId><ArticleId IdType="pmc">PMC8330131</ArticleId><ArticleId IdType="pubmed">34354712</ArticleId></ArticleIdList></Reference><Reference><Citation>Zohar T., Alter G. Dissecting antibody-mediated protection against SARS-CoV-2. Nat. Rev. Immunol. 2020;20:392&#x2013;394. doi: 10.1038/s41577-020-0359-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0359-5</ArticleId><ArticleId IdType="pmc">PMC7278217</ArticleId><ArticleId IdType="pubmed">32514035</ArticleId></ArticleIdList></Reference><Reference><Citation>Vetter P., Eberhardt C.S., Meyer B., Murillo P.A.M., Torriani G., Pigny F., Lemeille S., Cordey S., Laubscher F., Vu D.-L., et al. Daily viral kinetics and innate and adaptive immune response assessment in COVID-19: A case series. mSphere. 2020;5:e00827-20. doi: 10.1128/mSphere.00827-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00827-20</ArticleId><ArticleId IdType="pmc">PMC7657589</ArticleId><ArticleId IdType="pubmed">33177214</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J.M., Bai P., He W., Wu F., Liu X.F., Han D.M., Liu S., Yang J.K. Gender differences in patients with COVID-19: Focus on severity and mortality. Front. Public Health. 2020;8:152. doi: 10.3389/fpubh.2020.00152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.00152</ArticleId><ArticleId IdType="pmc">PMC7201103</ArticleId><ArticleId IdType="pubmed">32411652</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A., Madhavan M.V., Sehgal K., Nair N., Mahajan S., Sehrawat T.S., Bikdeli B., Ahluwalia N., Ausiello J.C., Wan E.Y., et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020;26:1017&#x2013;1032. doi: 10.1038/s41591-020-0968-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0968-3</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J., on behalf of the HLH Across Speciality Collaboration, UK COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033&#x2013;1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh M.K., Mobeen A., Chandra A., Joshi S., Ramachandran S. A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection? Comput. Biol. Med. 2021;130:104219. doi: 10.1016/j.compbiomed.2021.104219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.compbiomed.2021.104219</ArticleId><ArticleId IdType="pmc">PMC7836641</ArticleId><ArticleId IdType="pubmed">33486379</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal U., Azcoaga-Lorenzo A., Fagbamigbe A.F., Vasileiou E., Henery P., Simpson C.R., Stock S.J., Shah S.A., Robertson C., Woolhouse M., et al. Association between multimorbidity and mortality in a cohort of patients admitted to hospital with COVID-19 in Scotland. J. R. Soc. Med. 2021;115:22&#x2013;30. doi: 10.1177/01410768211051715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211051715</ArticleId><ArticleId IdType="pmc">PMC8811325</ArticleId><ArticleId IdType="pubmed">34672832</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of COVID-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;court C., Buxton M., Husain L. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>van Kampen J.J., van de Vijver D.A., Fraaij P.L., Haagmans B.L., Lamers M.M., Okba N., van den Akker J.P., Endeman H., Gommers D.A., Cornelissen J.J., et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19) Nat. Commun. 2021;12:267. doi: 10.1038/s41467-020-20568-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-20568-4</ArticleId><ArticleId IdType="pmc">PMC7801729</ArticleId><ArticleId IdType="pubmed">33431879</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A. Long COVID-19: Challenges in the diagnosis and proposed diagnostic criteria. Diabetes Metab. Syndr. Clin. Res. Rev. 2020;15:145&#x2013;146. doi: 10.1016/j.dsx.2020.12.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.12.025</ArticleId><ArticleId IdType="pmc">PMC7737559</ArticleId><ArticleId IdType="pubmed">33341598</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Ling S., Lui L.M., Lee Y., Gill H., Teopiz K.M., Rodrigues N.B., Subramaniapillai M., Di Vincenzo J.D., Cao B., et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun. 2021;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Bosworth M.L., King S., Pouwels K.B., Glickman M., Nafilyan V., Zaccardi F., Khunti K., Alwan N.A., Walker A.S. Risk of Long Covid in people infected with SARS-CoV-2 after two doses of a COVID-19 vaccine: Community-based, matched cohort study. medRxiv. 2022 doi: 10.1101/2022.02.23.22271388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.02.23.22271388</ArticleId><ArticleId IdType="pmc">PMC9494414</ArticleId><ArticleId IdType="pubmed">36168555</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., Myles P., Williams T., Gokhale K.M., Taverner T., Chandan J.S., Brown K., Simms-Williams N., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;28:1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Han Q., Zheng B., Daines L., Sheikh A. Long-term sequelae of COVID-19: A systematic review and meta-analysis of one-year follow-up studies on post-COVID symptoms. Pathogens. 2022;11:269. doi: 10.3390/pathogens11020269.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020269</ArticleId><ArticleId IdType="pmc">PMC8875269</ArticleId><ArticleId IdType="pubmed">35215212</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh I., Joseph P., Heerdt P.M., Cullinan M., Lutchmansingh D.D., Gulati M., Possick J.D., Systrom D.M., Waxman A.B. Persistent exertional intolerance after COVID-19: Insights from invasive cardiopulmonary exercise testing. Chest. 2022;161:54&#x2013;63. doi: 10.1016/j.chest.2021.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2021.08.010</ArticleId><ArticleId IdType="pmc">PMC8354807</ArticleId><ArticleId IdType="pubmed">34389297</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Townsend L., Morrin H., Ahmad A., Comerford C., Karampini E., Englert H., Byrne M., Bergin C., O&#x2019;sullivan J.M., et al. Persistent endotheliopathy in the pathogenesis of long COVID syndrome. J. Thromb. Haemost. 2021;19:2546&#x2013;2553. doi: 10.1111/jth.15490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15490</ArticleId><ArticleId IdType="pmc">PMC8420256</ArticleId><ArticleId IdType="pubmed">34375505</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., Yang Y., Li Y., Wang Z., Ma F., Luo R., Xu X., Zhou G., Wang J., Niu J., et al. Platelets mediate inflammatory monocyte activation by SARS-CoV-2 spike protein. J. Clin. Investig. 2022;132:e150101. doi: 10.1172/JCI150101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI150101</ArticleId><ArticleId IdType="pmc">PMC8843740</ArticleId><ArticleId IdType="pubmed">34964720</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobbelaar L.M., Venter C., Vlok M., Ngoepe M., Laubscher G.J., Lourens P.J., Steenkamp J., Kell D.B., Pretorius E. SARS-CoV-2 spike protein S1 induces fibrin (ogen) resistant to fibrinolysis: Implications for microclot formation in COVID-19. Biosci. Rep. 2021;41:BSR20210611. doi: 10.1042/BSR20210611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20210611</ArticleId><ArticleId IdType="pmc">PMC8380922</ArticleId><ArticleId IdType="pubmed">34328172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajaz S., McPhail M.J., Singh K.K., Mujib S., Trovato F.M., Napoli S., Agarwal K. Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19. Am. J. Physiol.-Cell Physiol. 2021;320:C57&#x2013;C65. doi: 10.1152/ajpcell.00426.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00426.2020</ArticleId><ArticleId IdType="pmc">PMC7816428</ArticleId><ArticleId IdType="pubmed">33151090</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsivgoulis G., Fragkou P.C., Lachanis S., Palaiodimou L., Lambadiari V., Papathanasiou M., Sfikakis P.P., Voumvourakis K.I., Tsiodras S. Olfactory bulb and mucosa abnormalities in persistent COVID-19-induced anosmia: A magnetic resonance imaging study. Eur. J. Neurol. 2020;28:E6&#x2013;E8. doi: 10.1111/ene.14537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14537</ArticleId><ArticleId IdType="pubmed">32939911</ArticleId></ArticleIdList></Reference><Reference><Citation>Brann D.H., Tsukahara T., Weinreb C., Lipovsek M., Van den Berge K., Gong B., Chance R., Macaulay I.C., Chou H.J., Fletcher R.B., et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci. Adv. 2020;6:eabc5801. doi: 10.1126/sciadv.abc5801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abc5801</ArticleId><ArticleId IdType="pmc">PMC10715684</ArticleId><ArticleId IdType="pubmed">32937591</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaira L.A., Hopkins C., Sandison A., Manca A., Machouchas N., Turilli D., Lechien J.R., Barillari M.R., Salzano G., Cossu A., et al. Olfactory epithelium histopathological findings in long-term coronavirus disease 2019 related anosmia. J. Laryngol. Otol. 2020;134:1123&#x2013;1127. doi: 10.1017/S0022215120002455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S0022215120002455</ArticleId><ArticleId IdType="pmc">PMC7729153</ArticleId><ArticleId IdType="pubmed">33190655</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis H.E., Mccorkell L., Vogel J.M., Topol E.J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 2023;21:133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M., Mercad&#xe9;-Besora N., Kolde R., Trinh N.T., Roel E., Burn E., Rathod-Mistry T., Kostka K., Man W.Y., Delmestri A., et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: Staggered cohort study of data from the UK, Spain, and Estonia. Lancet Respir. Med. 2024;12:225&#x2013;236. doi: 10.1016/S2213-2600(23)00414-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00414-9</ArticleId><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe A., Iwagami M., Yasuhara J., Takagi H., Kuno T. Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis. Vaccine. 2023;41:1783&#x2013;1790. doi: 10.1016/j.vaccine.2023.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.02.008</ArticleId><ArticleId IdType="pmc">PMC9905096</ArticleId><ArticleId IdType="pubmed">36774332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mccarthy M.W. Metformin as a potential treatment for COVID-19. Expert Opin. Pharmacother. 2023;24:1199&#x2013;1203. doi: 10.1080/14656566.2023.2215385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2023.2215385</ArticleId><ArticleId IdType="pubmed">37194484</ArticleId></ArticleIdList></Reference><Reference><Citation>Mccarthy M.W. Paxlovid as a potential treatment for long COVID. Expert Opin. Pharmacother. 2023;24:1839&#x2013;1843. doi: 10.1080/14656566.2023.2262387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2023.2262387</ArticleId><ArticleId IdType="pubmed">37731377</ArticleId></ArticleIdList></Reference><Reference><Citation>Knopman D.S., Laskowitz D.T., Koltai D.C., Charvet L.E., Becker J.H., Federman A.D., Wisnivesky J., Mahncke H., Van Vleet T.M., Bateman L., et al. RECOVER-NEURO: Study protocol for a multi-center, multi-arm, phase 2, randomized, active comparator trial evaluating three interventions for cognitive dysfunction in post-acute sequelae of SARS-CoV-2 infection (PASC) Trials. 2024;25:326. doi: 10.1186/s13063-024-08156-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-024-08156-z</ArticleId><ArticleId IdType="pmc">PMC11098733</ArticleId><ArticleId IdType="pubmed">38755688</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerman K. RECOVER-AUTONOMIC: A Platform Protocol for Evaluation of Interventions for Autonomic Dysfunction in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). [Online] 2024.  [(accessed on 30 June 2024)].  Available online:  https://trials.recovercovid.org/documents/RECOVER_AUTONOMIC_Protocol_V3.0.pdf.</Citation></Reference><Reference><Citation>Zimmerman K. RECOVER-SLEEP: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC). [Online] 2024.  [(accessed on 30 June 2024)].  Available online:  https://trials.recovercovid.org/documents/RECOVER_SLEEP_Protocol_V3.0.pdf.</Citation></Reference><Reference><Citation>Gao W., Lv J., Pang Y., Li L.-M. Role of asymptomatic and pre-symptomatic infections in COVID-19 pandemic. BMJ. 2021;375:n2342. doi: 10.1136/bmj.n2342.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2342</ArticleId><ArticleId IdType="pmc">PMC8634419</ArticleId><ArticleId IdType="pubmed">34852994</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindra K., Malik V., Padhi B., Goel S., Gupta M. Asymptomatic infection and transmission of COVID-19 among clusters: Systematic review and meta-analysis. Public Health. 2021;203:100&#x2013;109. doi: 10.1016/j.puhe.2021.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.puhe.2021.12.003</ArticleId><ArticleId IdType="pmc">PMC8654597</ArticleId><ArticleId IdType="pubmed">35038628</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayaweera M., Perera H., Gunawardana B., Manatunge J. Transmission of Null COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environ. Res. 2020;188:109819. doi: 10.1016/j.envres.2020.109819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.envres.2020.109819</ArticleId><ArticleId IdType="pmc">PMC7293495</ArticleId><ArticleId IdType="pubmed">32569870</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  In Vitro Diagnostics for COVID-19 [Online]  [(accessed on 6 July 2024)].  Available online:  https://www.who.int/teams/health-product-policy-and-standards/assistive-and-medical-technology/medical-devices/priority-medical-devices-for-covid/diagnostics-for-covid-19.</Citation></Reference><Reference><Citation>Food and Drug Administration  COVID-19 Test Basics [Online]  [(accessed on 6 July 2024)];2023  Available online:  https://www.fda.gov/consumers/consumer-updates/covid-19-test-basics.</Citation></Reference><Reference><Citation>Castellanos M., Somoza &#xc1;. Emerging clinically tested detection methods for COVID-19. FEBS J. 2022;290:3089&#x2013;3104. doi: 10.1111/febs.16469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.16469</ArticleId><ArticleId IdType="pmc">PMC9348311</ArticleId><ArticleId IdType="pubmed">35490403</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia R., Carvalho V., Faria B., Miranda I., Catarino S., Teixeira S., Lima R., Minas G., Ribeiro J. Diagnosis Methods for COVID-19: A Systematic Review. Micromachines. 2022;13:1349. doi: 10.3390/mi13081349.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/mi13081349</ArticleId><ArticleId IdType="pmc">PMC9415914</ArticleId><ArticleId IdType="pubmed">36014271</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong H., Zhang K., Zhang J., Xiao Y., Zhang F., Wang M., Wang H., Zhao G., Xie S., Xie X., et al. A fast RT-qPCR system significantly shortens the time for SARS-CoV-2 nucleic acid test. Drug Discov. Ther. 2023;17:37&#x2013;44. doi: 10.5582/ddt.2022.01092.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/ddt.2022.01092</ArticleId><ArticleId IdType="pubmed">36843076</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsang H.F., Leung W.M.S., Chan L.W.C., Cho W.C.S., Wong S.C.C. Performance comparison of the Cobas&#xae; Liat&#xae; and Cepheid&#xae; GeneXpert&#xae; systems on SARS-CoV-2 detection in nasopharyngeal swab and posterior oropharyngeal saliva. Expert Rev. Mol. Diagn. 2021;21:515&#x2013;518. doi: 10.1080/14737159.2021.1919513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2021.1919513</ArticleId><ArticleId IdType="pmc">PMC8095157</ArticleId><ArticleId IdType="pubmed">33906571</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan S.H., Allicock O., Armstrong-Hough M., Wyllie A.L. Saliva as a gold-standard sample for SARS-CoV-2 detection. Lancet Respir. Med. 2021;9:562&#x2013;564. doi: 10.1016/S2213-2600(21)00178-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00178-8</ArticleId><ArticleId IdType="pmc">PMC8055204</ArticleId><ArticleId IdType="pubmed">33887248</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Zhang X., Sun J., Ye J., Wang F., Hua J., Zhang H., Shi T., Li Q., Wu X. Differences of Severe Acute Respiratory Syndrome Coronavirus 2 Shedding Duration in Sputum and Nasopharyngeal Swab Specimens among Adult Inpatients with Coronavirus Disease 2019. Chest. 2020;158:1876&#x2013;1884. doi: 10.1016/j.chest.2020.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.06.015</ArticleId><ArticleId IdType="pmc">PMC7305751</ArticleId><ArticleId IdType="pubmed">32569635</ArticleId></ArticleIdList></Reference><Reference><Citation>Akowuah E., Acheampong G., Ayisi-Boateng N.K., Amaniampong A., Agyapong F.O., Senyo Kamasah J., Agyei G., Owusu D.O., Nkrumah B., Mutocheluh M., et al. Comparable Detection of SARS-CoV-2 in Sputum and Oropharyngeal Swab Samples of Suspected COVID-19 Patients. COVID. 2022;2:858&#x2013;866. doi: 10.3390/covid2070062.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/covid2070062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadzadeh M., Vahidi H., Mahboubi A., Hajifathaliha F., Nematollahi L., Mohit E. Different Respiratory Samples for COVID-19 Detection by Standard and Direct Quantitative RT-PCR: A Literature Review. Iran. J. Pharm. Res. IJPR. 2021;20:285&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8653661</ArticleId><ArticleId IdType="pubmed">34903989</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali D.Y., Hussein R.A., Elshafie S.M., Mohamed R.A., El Reheem F.A. Comparable detection of nasopharyngeal swabs and induced sputum specimens for viral nucleic acid detection of suspected novel coronavirus (SARS-Cov-2) patients in Fayoum governorate, Egypt. Beni-Suef Univ. J. Basic Appl. Sci. 2023;12:43. doi: 10.1186/s43088-023-00379-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43088-023-00379-4</ArticleId><ArticleId IdType="pmc">PMC10153783</ArticleId><ArticleId IdType="pubmed">37151720</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexandersen S., Chamings A., Bhatta T.R. SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication. Nat. Commun. 2020;11:6059. doi: 10.1038/s41467-020-19883-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19883-7</ArticleId><ArticleId IdType="pmc">PMC7695715</ArticleId><ArticleId IdType="pubmed">33247099</ArticleId></ArticleIdList></Reference><Reference><Citation>Maniruzzaman M., Islam M.M., Ali M.H., Mukerjee N., Maitra S., Kamal M.A., Ghosh A., Castrosanto M.A., Alexiou A., Ashraf G.M., et al. COVID-19 diagnostic methods in developing countries. Environ. Sci. Pollut. Res. Int. 2022;29:51384&#x2013;51397. doi: 10.1007/s11356-022-21041-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11356-022-21041-z</ArticleId><ArticleId IdType="pmc">PMC9135468</ArticleId><ArticleId IdType="pubmed">35619009</ArticleId></ArticleIdList></Reference><Reference><Citation>Jefferson T., Spencer E.A., Conly J.M., Rosca E.C., Maltoni S., Brassey J., Onakpoya I.J., Evans D.H., Heneghan C.J., Pl&#xfc;ddemann A. Viral cultures, cycle threshold values and viral load estimation for assessing SARS-CoV-2 infectiousness in haematopoietic stem cell and solid organ transplant patients: A systematic review. J. Hosp. Infect. 2023;132:62&#x2013;72. doi: 10.1016/j.jhin.2022.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhin.2022.11.018</ArticleId><ArticleId IdType="pmc">PMC9721162</ArticleId><ArticleId IdType="pubmed">36473552</ArticleId></ArticleIdList></Reference><Reference><Citation>Benevides Lima L., Mesquita F.P., Brasil de Oliveira L.L., Andr&#xe9;a da Silva Oliveira F., Elisabete Amaral de Moraes M., Souza P.F., Montenegro R.C. True or false: What are the factors that influence COVID-19 diagnosis by RT-qPCR? Expert Rev. Mol. Diagn. 2022;22:157&#x2013;167. doi: 10.1080/14737159.2022.2037425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2022.2037425</ArticleId><ArticleId IdType="pmc">PMC8862161</ArticleId><ArticleId IdType="pubmed">35130461</ArticleId></ArticleIdList></Reference><Reference><Citation>Udvardi M.K., Czechowski T., Scheible W.-R. Eleven golden rules of quantitative RT-PCR. Plant Cell. 2008;20:1736&#x2013;1737. doi: 10.1105/tpc.108.061143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1105/tpc.108.061143</ArticleId><ArticleId IdType="pmc">PMC2518243</ArticleId><ArticleId IdType="pubmed">18664613</ArticleId></ArticleIdList></Reference><Reference><Citation>Panchali M.J.L., Oh H.J., Lee Y.M., Kim C.-M., Tariq M., Seo J.-W., Kim D.Y., Yun N.R., Kim D.-M. Accuracy of Real-Time Polymerase Chain Reaction in COVID-19 Patients. Microbiol. Spectr. 2022;10:e0059121. doi: 10.1128/spectrum.00591-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.00591-21</ArticleId><ArticleId IdType="pmc">PMC8849071</ArticleId><ArticleId IdType="pubmed">35170995</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Lemus Y., Anaya-Romero M., G&#xf3;mez-Montoya J., &#xc1;rquez M., Gonz&#xe1;lez-Torres H.J., Navarro-Quiroz E., Pacheco-Londo&#xf1;o L., Pacheco-Lugo L., Acosta-Hoyos A.J. Comparative Analysis of In-House RT-qPCR Detection of SARS-CoV-2 for Resource-Constrained Settings. Diagnostics. 2022;12:2883. doi: 10.3390/diagnostics12112883.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12112883</ArticleId><ArticleId IdType="pmc">PMC9689939</ArticleId><ArticleId IdType="pubmed">36428942</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh K.A., Jordan K., Clyne B., Rohde D., Drummond L., Byrne P., Ahern S., Carty P.G., O&#x2019;Brien K.K., O&#x2019;Murchu E., et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. J. Infect. 2020;81:357&#x2013;371. doi: 10.1016/j.jinf.2020.06.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.06.067</ArticleId><ArticleId IdType="pmc">PMC7323671</ArticleId><ArticleId IdType="pubmed">32615199</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R., Yi S., Zhang J., Lv Z., Zhu C., Zhang Y. Viral Load Dynamics in Sputum and Nasopharyngeal Swab in Patients with COVID-19. J. Dent. Res. 2020;99:1239&#x2013;1244. doi: 10.1177/0022034520946251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0022034520946251</ArticleId><ArticleId IdType="pmc">PMC7399563</ArticleId><ArticleId IdType="pubmed">32744907</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng S., Fan J., Yu F., Feng B., Lou B., Zou Q., Xie G., Lin S., Wang R., Yang X., et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January&#x2013;March 2020: Retrospective cohort study. BMJ. 2020;369:m1443. doi: 10.1136/bmj.m1443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m1443</ArticleId><ArticleId IdType="pmc">PMC7190077</ArticleId><ArticleId IdType="pubmed">32317267</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration  In Vitro Diagnostics EUAs&#x2014;Molecular Diagnostic Tests for SARS-CoV-2 [Online]  [(accessed on 1 July 2024)];2024  Available online:  https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2.</Citation></Reference><Reference><Citation>Johns Hopkins Center for Health Security  Antigen and Molecular Tests for COVID-19 [Online] 2022.  [(accessed on 3 July 2024)].  Available online:  https://covid19testingtoolkit.centerforhealthsecurity.org/testing-trackers/antigen-and-molecular-tests-for-covid-19#lab.</Citation></Reference><Reference><Citation>Phan T., Valeriano P., Boes S., McCullough M., Gribschaw J., Wells A. Evaluation of the ePlex Respiratory pathogen panel 2 to detect viral and bacterial pathogens, including SARS-CoV-2 Omicron in nasopharyngeal swabs. J. Clin. Virol. Plus. 2022;2:100072. doi: 10.1016/j.jcvp.2022.100072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcvp.2022.100072</ArticleId><ArticleId IdType="pmc">PMC9578329</ArticleId><ArticleId IdType="pubmed">36277996</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahajpal N.S., Mondal A.K., Ananth S., Njau A., Jones K., Ahluwalia P., Oza E., Ross T.M., Kota V., Kothandaraman A., et al. Clinical validation of a multiplex PCR-based detection assay using saliva or nasopharyngeal samples for SARS-Cov-2, influenza A and B. Sci. Rep. 2022;12:3480. doi: 10.1038/s41598-022-07152-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-07152-0</ArticleId><ArticleId IdType="pmc">PMC8894395</ArticleId><ArticleId IdType="pubmed">35241679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi S.A., Safamanesh S., Ghasemzadeh-moghaddam H., Ghafouri M., Azimian A. High prevalence of SARS-CoV-2 and influenza A virus (H1N1) coinfection in dead patients in Northeastern Iran. J. Med. Virol. 2021;93:1008&#x2013;1012. doi: 10.1002/jmv.26364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26364</ArticleId><ArticleId IdType="pubmed">32720703</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Z., Zhang Y., Hang C., Ai J., Li S., Zhang W. Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients. J. Infect. 2020;81:147&#x2013;178. doi: 10.1016/j.jinf.2020.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.03.013</ArticleId><ArticleId IdType="pmc">PMC7118636</ArticleId><ArticleId IdType="pubmed">32209381</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong L., Zhou J., Niu C., Wang Q., Pan Y., Sheng S., Wang X., Zhang Y., Yang J., Liu M., et al. Highly accurate and sensitive diagnostic detection of SARS-CoV-2 by digital PCR. Talanta. 2021;224:121726. doi: 10.1016/j.talanta.2020.121726.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.talanta.2020.121726</ArticleId><ArticleId IdType="pmc">PMC7588801</ArticleId><ArticleId IdType="pubmed">33379001</ArticleId></ArticleIdList></Reference><Reference><Citation>Suo T., Liu X., Feng J., Guo M., Hu W., Guo D., Ullah H., Yang Y., Zhang Q., Wang X., et al. ddPCR: A more accurate tool for SARS-CoV-2 detection in low viral load specimens. Emerg. Microbes Infect. 2020;9:1259&#x2013;1268. doi: 10.1080/22221751.2020.1772678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1772678</ArticleId><ArticleId IdType="pmc">PMC7448897</ArticleId><ArticleId IdType="pubmed">32438868</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhar B.C. Diagnostic assay and technology advancement for detecting SARS-CoV-2 infections causing the COVID-19 pandemic. Anal. Bioanal. Chem. 2022;414:2903&#x2013;2934. doi: 10.1007/s00216-022-03918-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00216-022-03918-7</ArticleId><ArticleId IdType="pmc">PMC8872642</ArticleId><ArticleId IdType="pubmed">35211785</ArticleId></ArticleIdList></Reference><Reference><Citation>Shafie M.H., Antony Dass M., Ahmad Shaberi H.S., Zafarina Z. Screening and confirmation tests for SARS-CoV-2: Benefits and drawbacks. Beni Suef Univ. J. Basic Appl. Sci. 2023;12:6. doi: 10.1186/s43088-023-00342-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43088-023-00342-3</ArticleId><ArticleId IdType="pmc">PMC9833029</ArticleId><ArticleId IdType="pubmed">36647397</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi G., Moehling T.J., Meagher R.J. Advances in RT-LAMP for COVID-19 testing and diagnosis. Expert Rev. Mol. Diagn. 2023;23:9&#x2013;28. doi: 10.1080/14737159.2023.2169071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737159.2023.2169071</ArticleId><ArticleId IdType="pubmed">36695788</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Ma Y., Song Z., Sun W., Liu Y., Shu C., Hua H., Yang M., Liang Q. Evaluation of an automated CRISPR-based diagnostic tool for rapid detection of COVID-19. Heliyon. 2023;9:e13190. doi: 10.1016/j.heliyon.2023.e13190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e13190</ArticleId><ArticleId IdType="pmc">PMC9868009</ArticleId><ArticleId IdType="pubmed">36712915</ArticleId></ArticleIdList></Reference><Reference><Citation>New England Biolabs  Loop-Mediated Isothermal Amplification [Online]  [(accessed on 15 May 2024)].  Available online:  https://www.neb.com/en/applications/dna-amplification-pcr-and-qpcr/isothermal-amplification/loop-mediated-isothermal-amplification-lamp.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Interim Guidelines for COVID-19 Antibody Testing in Clinical and Public Health Settings [Online]  [(accessed on 10 April 2024)];2022  Available online:  https://www.cdc.gov/coronavirus/2019-ncov/hcp/testing/antibody-tests-guidelines.html.</Citation></Reference><Reference><Citation>Food and Drug Administration  Antibody (Serology) Testing for COVID-19: Information for Patients and Consumers [Online]  [(accessed on 10 April 2024)];2023  Available online:  https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/antibody-serology-testing-covid-19-information-patients-and-consumers.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Considerations for SARS-CoV-2 Antigen Testing for Healthcare Providers Testing Individuals in the Community [Online]  [(accessed on 10 April 2024)];2023  Available online:  https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html.</Citation></Reference><Reference><Citation>American Society for Microbiology  How the SARS-CoV-2 EUA Antigen Tests Work [Online] 2020.  [(accessed on 10 April 2024)].  Available online:  https://asm.org/articles/2020/august/how-the-sars-cov-2-eua-antigen-tests-work.</Citation></Reference><Reference><Citation>Hashim I.A., editor. Tutorials in Clinical Chemistry. Elsevier; Amsterdam, The Netherlands: 2024. Chapter 17&#x2014;Analytical methods and special considerations.</Citation></Reference><Reference><Citation>Food and Drug Administration  At Home OTC COVID-19 Diagnostic Tests [Online]  [(accessed on 10 April 2024)];2024  Available online:  https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/home-otc-covid-19-diagnostic-tests.</Citation></Reference><Reference><Citation>Katzenschlager S., Bruemmer L.E., Schmitz S., Tolle H., Manten K., Gaeddert M., Erdmann C., Lindner A., Tobian F., Grilli M., et al. Comparing SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing/self-sampling with molecular and professional-use tests: A systematic review and meta-analysis. Sci. Rep. 2023;13:21913. doi: 10.1038/s41598-023-48892-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-48892-x</ArticleId><ArticleId IdType="pmc">PMC10713601</ArticleId><ArticleId IdType="pubmed">38081881</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadegari H., Mohammadi M., Maghsood F., Ghorbani A., Bahadori T., Golsaz-Shirazi F., Zarnani A.H., Salimi V., Jeddi-Tehrani M., Amiri M.M., et al. Diagnostic performance of a novel antigen-capture ELISA for the detection of SARS-CoV-2. Anal. Biochem. 2023;666:115079. doi: 10.1016/j.ab.2023.115079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ab.2023.115079</ArticleId><ArticleId IdType="pmc">PMC9902293</ArticleId><ArticleId IdType="pubmed">36754135</ArticleId></ArticleIdList></Reference><Reference><Citation>Adnan N., Khandker S.S., Haq A., Chaity M.A., Khalek A., Nazim A.Q., Kaitsuka T., Tomizawa K., Mie M., Kobatake E., et al. Detection of SARS-CoV-2 by antigen ELISA test is highly swayed by viral load and sample storage condition. Expert Rev. Anti-Infect. Ther. 2022;20:473&#x2013;481. doi: 10.1080/14787210.2021.1976144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2021.1976144</ArticleId><ArticleId IdType="pmc">PMC8442762</ArticleId><ArticleId IdType="pubmed">34477019</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss A., Jellings&#xf8; M., Sommer M.O.A. Spatial and temporal dynamics of SARS-CoV-2 in COVID-19 patients: A systematic review and meta-analysis. eBioMedicine. 2020;58:102916. doi: 10.1016/j.ebiom.2020.102916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102916</ArticleId><ArticleId IdType="pmc">PMC7374142</ArticleId><ArticleId IdType="pubmed">32711256</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin H., Li Y., Wu P., Li Z., Lau E.H.Y., Qin Y., Wang L., Cowling B.J., Tsang T.K., Li Z. Estimating the Latent Period of Coronavirus Disease 2019 (COVID-19) Clin. Infect. Dis. 2021;74:1678&#x2013;1681. doi: 10.1093/cid/ciab746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab746</ArticleId><ArticleId IdType="pubmed">34453527</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361&#x2013;379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagag I.T., Pyrc K., Weber S., Balkema-Buschmann A., Groschup M.H., Keller M. Mutations in SARS-CoV-2 nucleocapsid in variants of concern impair the sensitivity of SARS-CoV-2 detection by rapid antigen tests. Front. Virol. 2022;2:971862. doi: 10.3389/fviro.2022.971862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fviro.2022.971862</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N., Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D., et al. Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis. PLoS Pathog. 2022;18:e1010627. doi: 10.1371/journal.ppat.1010627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010627</ArticleId><ArticleId IdType="pmc">PMC9275689</ArticleId><ArticleId IdType="pubmed">35728038</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Daly M.M. Advances and Challenges in SARS-CoV-2 Detection: A Review of Molecular and Serological Technologies. Diagnostics. 2024;14:519. doi: 10.3390/diagnostics14050519.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics14050519</ArticleId><ArticleId IdType="pmc">PMC10931201</ArticleId><ArticleId IdType="pubmed">38472991</ArticleId></ArticleIdList></Reference><Reference><Citation>Udugama B., Kadhiresan P., Kozlowski H.N., Malekjahani A., Osborne M., Li V.Y.C., Chen H., Mubareka S., Gubbay J.B., Chan W.C.W. Diagnosing COVID-19: The Disease and Tools for Detection. ACS Nano. 2020;14:3822&#x2013;3835. doi: 10.1021/acsnano.0c02624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsnano.0c02624</ArticleId><ArticleId IdType="pubmed">32223179</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y.Z., Holmes E.C. A Genomic Perspective on the Origin and Emergence of SARS-CoV-2. Cell. 2020;181:223&#x2013;227. doi: 10.1016/j.cell.2020.03.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.035</ArticleId><ArticleId IdType="pmc">PMC7194821</ArticleId><ArticleId IdType="pubmed">32220310</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  Genomic Sequencing of SARS-CoV-2: A Guide to Implementation for Maximum Impact on Public Health. 8 January 2021.  [(accessed on 24 July 2024)].  Available online:  https://www.who.int/publications/i/item/9789240018440.</Citation></Reference><Reference><Citation>ImmunoDiagnostics  SARS-CoV-2 NP Ab ELISA Kit [CE-IVD] [Online]  [(accessed on 3 July 2024)].  Available online:  https://www.immunodiagnostics.com.hk/product-page/sars-cov-2-np-ab-elisa-kit-ce-ivd.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  Understanding How COVID-19 Vaccines Work [Online]  [(accessed on 3 July 2024)];2023  Available online:  https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html.</Citation></Reference><Reference><Citation>Carabelli A.M., Peacock T.P., Thorne L.G., Harvey W.T., Hughes J., Peacock S.J., Barclay W.S., De Silva T.I., Towers G.J., Robertson D.L. SARS-CoV-2 variant biology: Immune escape, transmission and fitness. Nat. Rev. Microbiol. 2023;21:162&#x2013;177. doi: 10.1038/s41579-022-00841-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00841-7</ArticleId><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Papa Mze N., Kacel I., Beye M., Tola R., Sarr M., Basco L., Bogreau H., Colson P., Fournier P.E. High Throughput SARS-CoV-2 Genome Sequencing from 384 Respiratory Samples Using the Illumina COVIDSeq Protocol. Genes. 2023;14:681. doi: 10.3390/genes14030681.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes14030681</ArticleId><ArticleId IdType="pmc">PMC10048438</ArticleId><ArticleId IdType="pubmed">36980953</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox T., Geppert J., Dinnes J., Scandrett K., Bigio J., Sulis G., Hettiarachchi D., Mathangasinghe Y., Weeratunga P., Wickramasinghe D., et al. Antibody tests for identification of current and past infection with SARS-CoV-2. Cochrane Database Syst. Rev. 2022;6:cd013652. doi: 10.1002/14651858.CD013652.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD013652.pub2</ArticleId><ArticleId IdType="pmc">PMC9671206</ArticleId><ArticleId IdType="pubmed">36394900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontou P.I., Braliou G.G., Dimou N.L., Nikolopoulos G., Bagos P.G. Antibody Tests in Detecting SARS-CoV-2 Infection: A Meta-Analysis. Diagnostics. 2020;10:319. doi: 10.3390/diagnostics10050319.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics10050319</ArticleId><ArticleId IdType="pmc">PMC7278002</ArticleId><ArticleId IdType="pubmed">32438677</ArticleId></ArticleIdList></Reference><Reference><Citation>Matinfar S., Mortezagholi S., Amiri D., Pashaiefar H., Eskandarian M., Ghadimi S., Nazari M.F., Tavakoli S., Valizadeh M., Namaki S., et al. Investigating the Seroconversion Patterns of Specific Antibodies against Various Antigens of SARS-CoV-2 in Hospitalized COVID-19 Patients and Vaccinated Individuals. Arch. Clin. Infect. Dis. 2024;19:e140414. doi: 10.5812/archcid-140414.</Citation><ArticleIdList><ArticleId IdType="doi">10.5812/archcid-140414</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai K., Kitagawa Y., Tabata S., Kubota K., Nagura-Ikeda M., Matsuoka M., Miyoshi K., Sakai J., Ishibashi N., Tarumoto N., et al. Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. J. Med. Virol. 2021;93:3211&#x2013;3218. doi: 10.1002/jmv.26899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26899</ArticleId><ArticleId IdType="pmc">PMC8014305</ArticleId><ArticleId IdType="pubmed">33620098</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano Y., Kurano M., Morita Y., Shimura T., Yokoyama R., Qian C., Xia F., He F., Kishi Y., Okada J., et al. Time course of the sensitivity and specificity of anti-SARS-CoV-2 IgM and IgG antibodies for symptomatic COVID-19 in Japan. Sci. Rep. 2021;11:2776. doi: 10.1038/s41598-021-82428-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-82428-5</ArticleId><ArticleId IdType="pmc">PMC7854735</ArticleId><ArticleId IdType="pubmed">33531605</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Q.X., Liu B.Z., Deng H.J., Wu G.C., Deng K., Chen Y.K., Liao P., Qiu J.F., Lin Y., Cai X.F., et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 2020;26:845&#x2013;848. doi: 10.1038/s41591-020-0897-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0897-1</ArticleId><ArticleId IdType="pubmed">32350462</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharjee B., Rynjah D., Ahmed A.B., Newar A., Sengupta S., Chakrabarty S., Sahu R.K., Khan J. Overview of diagnostic tools and nano-based therapy of SARS-CoV-2 infection. Chem. Pap. 2024;78:2123&#x2013;2154. doi: 10.1007/s11696-023-03271-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11696-023-03271-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration  In Vitro Diagnostics Emergency Use Authorizations (EUAs)&#x2014;Serology and Other Adaptive Immune Response Tests for SARS-CoV-2 [Online]  [(accessed on 3 July 2024)];2024  Available online:  https://www.fda.gov/medical-devices/covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-emergency-use-authorizations-euas-serology-and-other-adaptive-immune-response.</Citation></Reference><Reference><Citation>Augustine R., Das S., Hasan A., Abdul Salam S., Augustine P., Dalvi Y.B., Varghese R., Primavera R., Yassine H.M., Thakor A.S., et al. Rapid antibody-based COVID-19 mass surveillance: Relevance, challenges, and prospects in a pandemic and post-pandemic world. J. Clin. Med. 2020;9:3372. doi: 10.3390/jcm9103372.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9103372</ArticleId><ArticleId IdType="pmc">PMC7589650</ArticleId><ArticleId IdType="pubmed">33096742</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimech W., Curley S., Subissi L., Str&#xf6;her U., Perkins M.D., Cunningham J. Comprehensive, Comparative Evaluation of 35 Manual SARS-CoV-2 Serological Assays. Microbiol. Spectr. 2023;11:e05101-22. doi: 10.1128/spectrum.05101-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.05101-22</ArticleId><ArticleId IdType="pmc">PMC10269659</ArticleId><ArticleId IdType="pubmed">37158743</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimech W., Curley S., Cai J.J. Comprehensive, comparative evaluation of 25 automated SARS-CoV-2 serology assays. Microbiol. Spectr. 2024;12:e03228-23. doi: 10.1128/spectrum.03228-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.03228-23</ArticleId><ArticleId IdType="pmc">PMC10783060</ArticleId><ArticleId IdType="pubmed">38018986</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Hilgenfeld R., Whitley R., De Clercq E. Therapeutic strategies for COVID-19: Progress and lessons learned. Nat. Rev. Drug Discov. 2023;22:449&#x2013;475. doi: 10.1038/s41573-023-00672-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-023-00672-y</ArticleId><ArticleId IdType="pmc">PMC10113999</ArticleId><ArticleId IdType="pubmed">37076602</ArticleId></ArticleIdList></Reference><Reference><Citation>Eastman R.T., Roth J.S., Brimacombe K.R., Simeonov A., Shen M., Patnaik S., Hall M.D. Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. ACS Central Sci. 2020;6:672&#x2013;683. doi: 10.1021/acscentsci.0c00489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acscentsci.0c00489</ArticleId><ArticleId IdType="pmc">PMC7202249</ArticleId><ArticleId IdType="pubmed">32483554</ArticleId></ArticleIdList></Reference><Reference><Citation>Barghash R.F., Fawzy I.M., Chandrasekar V., Singh A.V., Katha U., Mandour A.A. In Silico Modeling as a Perspective in Developing Potential Vaccine Candidates and Therapeutics for COVID-19. Coatings. 2021;11:1273. doi: 10.3390/coatings11111273.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/coatings11111273</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb R.L., Vaca C.E., Paredes R., Mera J., Webb B.J., Perez G., Oguchi G., Ryan P., Nielsen B.U., Brown M., et al. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N. Engl. J. Med. 2021;386:305&#x2013;315. doi: 10.1056/NEJMoa2116846.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116846</ArticleId><ArticleId IdType="pmc">PMC8757570</ArticleId><ArticleId IdType="pubmed">34937145</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al. Remdesivir for the Treatment of COVID-19&#x2014;Final Report. N. Engl. J. Med. 2020;383:1813&#x2013;1826. doi: 10.1056/NEJMoa2007764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pmc">PMC7262788</ArticleId><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Wang Z. Can remdesivir and its parent nucleoside GS-441524 be potential oral drugs? An in vitro and in vivo DMPK assessment. Acta Pharm. Sin. B. 2021;11:1607&#x2013;1616. doi: 10.1016/j.apsb.2021.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.03.028</ArticleId><ArticleId IdType="pmc">PMC8245906</ArticleId><ArticleId IdType="pubmed">34221871</ArticleId></ArticleIdList></Reference><Reference><Citation>Ader F., Bouscambert-Duchamp M., Hites M., Peiffer-Smadja N., Poissy J., Belhadi D., Diallo A., L&#xea; M.-P., Peytavin G., Staub T., et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): A phase 3, randomised, controlled, open-label trial. Lancet Infect. Dis. 2021;22:209&#x2013;221. doi: 10.1016/S1473-3099(21)00485-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00485-0</ArticleId><ArticleId IdType="pmc">PMC8439621</ArticleId><ArticleId IdType="pubmed">34534511</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan H., Peto R., Restrepo A.M.H., Preziosi M.-P., Sathiyamoorthy V., Karim Q.A., Alejandria M., Garc&#xed;a C.H., Kieny M.-P., Malekzadeh R., et al. Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet. 2022;399:1941&#x2013;1953. doi: 10.1016/S0140-6736(22)00519-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00519-0</ArticleId><ArticleId IdType="pmc">PMC9060606</ArticleId><ArticleId IdType="pubmed">35512728</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil A.C., Patterson T.F., Mehta A.K., Tomashek K.M., Wolfe C.R., Ghazaryan V., Marconi V.C., Ruiz-Palacios G.M., Hsieh L., Kline S., et al. Baricitinib plus Remdesivir for Hospitalized Adults with COVID-19. N. Engl. J. Med. 2021;384:795&#x2013;807. doi: 10.1056/NEJMoa2031994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil A.C., Mehta A.K., Patterson T.F., Erdmann N., Gomez C.A., Jain M.K., Wolfe C.R., Ruiz-Palacios G.M., Kline S., Pineda J.R., et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2021;9:1365&#x2013;1376. doi: 10.1016/S2213-2600(21)00384-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00384-2</ArticleId><ArticleId IdType="pmc">PMC8523116</ArticleId><ArticleId IdType="pubmed">34672949</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., Maggi F., McConnell S., Casadevall A. Very low levels of remdesivir resistance in SARS-CoV-2 genomes after 18 months of massive usage during the COVID19 pandemic: A GISAID exploratory analysis. Antivir. Res. 2022;198:105247. doi: 10.1016/j.antiviral.2022.105247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105247</ArticleId><ArticleId IdType="pmc">PMC8755559</ArticleId><ArticleId IdType="pubmed">35033572</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedskog C., Rodriguez L., Roychoudhury P., Huang M.-L., Jerome K.R., Hao L., Ireton R.C., Li J., Perry J.K., Han D., et al. Viral Resistance Analyses from the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1) J. Infect. Dis. 2023;228:1263&#x2013;1273. doi: 10.1093/infdis/jiad270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiad270</ArticleId><ArticleId IdType="pmc">PMC10629708</ArticleId><ArticleId IdType="pubmed">37466213</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangeel L., Chiu W., De Jonghe S., Maes P., Slechten B., Raymenants J., Andr&#xe9; E., Leyssen P., Neyts J., Jochmans D. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antivir. Res. 2022;198:105252. doi: 10.1016/j.antiviral.2022.105252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2022.105252</ArticleId><ArticleId IdType="pmc">PMC8785409</ArticleId><ArticleId IdType="pubmed">35085683</ArticleId></ArticleIdList></Reference><Reference><Citation>Uraki R., Ito M., Kiso M., Yamayoshi S., Iwatsuki-Horimoto K., Sakai-Tagawa Y., Imai M., Koga M., Yamamoto S., Adachi E., et al. Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate. iScience. 2023;26:108147. doi: 10.1016/j.isci.2023.108147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.108147</ArticleId><ArticleId IdType="pmc">PMC10590837</ArticleId><ArticleId IdType="pubmed">37876803</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitts J., Li J., Perry J.K., Du Pont V., Riola N., Rodriguez L., Lu X., Kurhade C., Xie X., Camus G., et al. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. Antimicrob. Agents Chemother. 2022;66:e0022222. doi: 10.1128/aac.00222-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.00222-22</ArticleId><ArticleId IdType="pmc">PMC9211395</ArticleId><ArticleId IdType="pubmed">35532238</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Z., Gao W., Bao H., Feng H., Mei S., Chen P., Gao Y., Cui Z., Zhang Q., Meng X., et al. VV116 versus Nirmatrelvir&#x2013;Ritonavir for Oral Treatment of COVID-19. N. Engl. J. Med. 2023;388:406&#x2013;417. doi: 10.1056/NEJMoa2208822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2208822</ArticleId><ArticleId IdType="pmc">PMC9812289</ArticleId><ArticleId IdType="pubmed">36577095</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X., Dai X., Ling Y., Wu L., Tang L., Peng C., Huang C., Liu H., Lu H., Shen X., et al. Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: A multicentre, double-blind, phase 3, randomised controlled study. Lancet Infect. Dis. 2024;24:129&#x2013;139. doi: 10.1016/S1473-3099(23)00577-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00577-7</ArticleId><ArticleId IdType="pubmed">38006892</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemian S.M., Sheida A., Taghizadieh M., Memar M.Y., Hamblin M.R., Baghi H.B., Nahand J.S., Asemi Z., Mirzaei H. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to COVID-19 therapy? Biomed. Pharmacother. 2023;162:114367. doi: 10.1016/j.biopha.2023.114367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2023.114367</ArticleId><ArticleId IdType="pmc">PMC9899776</ArticleId><ArticleId IdType="pubmed">37018987</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W., Zheng Y., Zeng X., He B., Cheng W. Structural biology of SARS-CoV-2: Open the door for novel therapies. Signal Transduct. Target. Ther. 2022;7:26. doi: 10.1038/s41392-022-00884-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00884-5</ArticleId><ArticleId IdType="pmc">PMC8793099</ArticleId><ArticleId IdType="pubmed">35087058</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S., Rox K., Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved &#x3b1;-ketoamide inhibitors. Science. 2020;368:409&#x2013;412. doi: 10.1126/science.abb3405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb3405</ArticleId><ArticleId IdType="pmc">PMC7164518</ArticleId><ArticleId IdType="pubmed">32198291</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammond J., Leister-Tebbe H., Gardner A., Abreu P., Bao W., Wisemandle W., Baniecki M., Hendrick V.M., Damle B., Sim&#xf3;n-Campos A., et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19. N. Engl. J. Med. 2022;386:1397&#x2013;1408. doi: 10.1056/NEJMoa2118542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C.K.H., Lau J.J., Au I.C.H., Lau K.T.K., Hung I.F.N., Peiris M., Leung G.M., Wu J.T. Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: Target trial emulation. Nat. Commun. 2023;14:8377. doi: 10.1038/s41467-023-43706-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-43706-0</ArticleId><ArticleId IdType="pmc">PMC10725470</ArticleId><ArticleId IdType="pubmed">38104114</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R., Sagy Y.W., Hoshen M., Battat E., Lavie G., Sergienko R., Friger M., Waxman J.G., Dagan N., Balicer R., et al. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge. N. Engl. J. Med. 2022;387:790&#x2013;798. doi: 10.1056/NEJMoa2204919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204919</ArticleId><ArticleId IdType="pmc">PMC9454652</ArticleId><ArticleId IdType="pubmed">36001529</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Wang Y., Lavrijsen M., Lamers M.M., de Vries A.C., Rottier R.J., Bruno M.J., Peppelenbosch M.P., Haagmans B.L., Pan Q. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022;32:322&#x2013;324. doi: 10.1038/s41422-022-00618-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00618-w</ArticleId><ArticleId IdType="pmc">PMC8771185</ArticleId><ArticleId IdType="pubmed">35058606</ArticleId></ArticleIdList></Reference><Reference><Citation>Greasley S.E., Noell S., Plotnikova O., Ferre R., Liu W., Bolanos B., Fennell K., Nicki J., Craig T., Zhu Y., et al. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants. J. Biol. Chem. 2022;298:101972. doi: 10.1016/j.jbc.2022.101972.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2022.101972</ArticleId><ArticleId IdType="pmc">PMC9023115</ArticleId><ArticleId IdType="pubmed">35461811</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashita E., Kinoshita N., Yamayoshi S., Sakai-Tagawa Y., Fujisaki S., Ito M., Iwatsuki-Horimoto K., Halfmann P., Watanabe S., Maeda K., et al. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2. N. Engl. J. Med. 2022;386:1475&#x2013;1477. doi: 10.1056/NEJMc2201933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2201933</ArticleId><ArticleId IdType="pmc">PMC8929374</ArticleId><ArticleId IdType="pubmed">35263535</ArticleId></ArticleIdList></Reference><Reference><Citation>Takashita E., Yamayoshi S., Simon V., van Bakel H., Sordillo E.M., Pekosz A., Fukushi S., Suzuki T., Maeda K., Halfmann P., et al. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants. N. Engl. J. Med. 2022;387:468&#x2013;470. doi: 10.1056/NEJMc2207519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2207519</ArticleId><ArticleId IdType="pmc">PMC9342381</ArticleId><ArticleId IdType="pubmed">35857646</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito A., Tamura T., Zahradnik J., Deguchi S., Tabata K., Anraku Y., Kimura I., Ito J., Yamasoba D., Nasser H., et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant. Cell Host Microbe. 2022;30:1540&#x2013;1555.e15. doi: 10.1016/j.chom.2022.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.10.003</ArticleId><ArticleId IdType="pmc">PMC9578327</ArticleId><ArticleId IdType="pubmed">36272413</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai M., Ito M., Kiso M., Yamayoshi S., Uraki R., Fukushi S., Watanabe S., Suzuki T., Maeda K., Sakai-Tagawa Y., et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB. N. Engl. J. Med. 2023;388:89&#x2013;91. doi: 10.1056/NEJMc2214302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214302</ArticleId><ArticleId IdType="pmc">PMC9749618</ArticleId><ArticleId IdType="pubmed">36476720</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal N.R., Molina K.C., Beaty L.E., Bennett T.D., Carlson N.E., Mayer D.A., Peers J.L., Russell S., Wynia M.K., Ginde A.A. Real-world use of nirmatrelvir&#x2013;ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: A retrospective cohort study. Lancet Infect. Dis. 2023;23:696&#x2013;705. doi: 10.1016/S1473-3099(23)00011-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00011-7</ArticleId><ArticleId IdType="pmc">PMC10014040</ArticleId><ArticleId IdType="pubmed">36780912</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Kelly S.P., Liang C., Li L., Shen R., Leister-Tebbe H.K., Terra S.G., Gaffney M., Russo L. Real-World Effectiveness of Nirmatrelvir/Ritonavir in Preventing Hospitalization among Patients with COVID-19 at High Risk for Severe Disease in the United States: A Nationwide Population-Based Cohort Study. medRxiv. 2022 doi: 10.1101/2022.09.13.22279908.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.09.13.22279908</ArticleId></ArticleIdList></Reference><Reference><Citation>Cegolon L., Pol R., Simonetti O., Filon F.L., Luzzati R. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life. Pharmaceuticals. 2023;16:721. doi: 10.3390/ph16050721.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph16050721</ArticleId><ArticleId IdType="pmc">PMC10221734</ArticleId><ArticleId IdType="pubmed">37242504</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S., Mohri H., Culbertson B., Hong S.J., Duan Y., Luck M.I., Annavajhala M.K., Guo Y., Sheng Z., Uhlemann A.-C., et al. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. Nature. 2022;613:558&#x2013;564. doi: 10.1038/s41586-022-05514-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05514-2</ArticleId><ArticleId IdType="pmc">PMC9849135</ArticleId><ArticleId IdType="pubmed">36351451</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Y., Zhou H., Liu X., Iketani S., Lin M., Zhang X., Bian Q., Wang H., Sun H., Hong S.J., et al. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023;622:376&#x2013;382. doi: 10.1038/s41586-023-06609-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-023-06609-0</ArticleId><ArticleId IdType="pubmed">37696289</ArticleId></ArticleIdList></Reference><Reference><Citation>Charness M.E., Gupta K., Stack G., Strymish J., Adams E., Lindy D.C., Mohri H., Ho D.D. Rebound of SARS-CoV-2 Infection after Nirmatrelvir&#x2013;Ritonavir Treatment. N. Engl. J. Med. 2022;387:1045&#x2013;1047. doi: 10.1056/NEJMc2206449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2206449</ArticleId><ArticleId IdType="pmc">PMC9511633</ArticleId><ArticleId IdType="pubmed">36069968</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L., Berger N.A., Davis P.B., Kaelber D.C., Volkow N.D., Xu R. COVID-19 rebound after Paxlovid and Molnupiravir during January&#x2013;June 2022. MedRxiv. 2022 doi: 10.1101/2022.06.21.22276724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.06.21.22276724</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson A.S., Caubel P., Rusnak J.M. Nirmatrelvir&#x2013;Ritonavir and Viral Load Rebound in COVID-19. N. Engl. J. Med. 2022;387:1047&#x2013;1049. doi: 10.1056/NEJMc2205944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2205944</ArticleId><ArticleId IdType="pmc">PMC9513855</ArticleId><ArticleId IdType="pubmed">36069818</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C.K.H., Lau K.T.K., Au I.C.H., Lau E.H.Y., Poon L.L.M., Hung I.F.N., Cowling B.J., Leung G.M. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: A population-wide retrospective cohort study. Lancet Infect. Dis. 2023;23:683&#x2013;695. doi: 10.1016/S1473-3099(22)00873-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00873-8</ArticleId><ArticleId IdType="pmc">PMC9949892</ArticleId><ArticleId IdType="pubmed">36796397</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong G.L.-H., Yip T.C.-F., Lai M.S.-M., Wong V.W.-S., Hui D.S.-C., Lui G.C.-Y. Incidence of Viral Rebound after Treatment with Nirmatrelvir-Ritonavir and Molnupiravir. JAMA Netw. Open. 2022;5:e2245086. doi: 10.1001/jamanetworkopen.2022.45086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.45086</ArticleId><ArticleId IdType="pmc">PMC9856258</ArticleId><ArticleId IdType="pubmed">36472873</ArticleId></ArticleIdList></Reference><Reference><Citation>Perelson A.S., Ribeiro R.M., Phan T. An explanation for SARS-CoV-2 rebound after Paxlovid treatment. medRxiv. 2023 doi: 10.1101/2023.05.30.23290747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.05.30.23290747</ArticleId></ArticleIdList></Reference><Reference><Citation>Boucau J., Uddin R., Marino C., Regan J., Flynn J.P., Choudhary M.C., Chen G., Stuckwisch A.M., Mathews J., Liew M.Y., et al. Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19) Clin. Infect. Dis. 2022;76:e526&#x2013;e529. doi: 10.1093/cid/ciac512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac512</ArticleId><ArticleId IdType="pmc">PMC9384370</ArticleId><ArticleId IdType="pubmed">35737946</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlin A.F., Clark A.E., Chaillon A., Garretson A.F., Bray W., Porrachia M., Santos A.T., Rana T.M., Smith D.M. Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment. Clin. Infect. Dis. 2022;76:e530&#x2013;e532. doi: 10.1093/cid/ciac496.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac496</ArticleId><ArticleId IdType="pmc">PMC9278181</ArticleId><ArticleId IdType="pubmed">35723411</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang J., Zhou C., Deng J., Zhou J. JAK inhibition as a new treatment strategy for patients with COVID-19. Biochem. Pharmacol. 2022;202:115162. doi: 10.1016/j.bcp.2022.115162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2022.115162</ArticleId><ArticleId IdType="pmc">PMC9250821</ArticleId><ArticleId IdType="pubmed">35787993</ArticleId></ArticleIdList></Reference><Reference><Citation>Satarker S., Tom A.A., Shaji R.A., Alosious A., Luvis M., Nampoothiri M. JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy. Postgrad. Med. 2020;133:489&#x2013;507. doi: 10.1080/00325481.2020.1855921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00325481.2020.1855921</ArticleId><ArticleId IdType="pmc">PMC7784782</ArticleId><ArticleId IdType="pubmed">33245005</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y. A review of Janus kinase inhibitors for the treatment of COVID-19 pneumonia. Inflamm. Regen. 2023;43:3. doi: 10.1186/s41232-022-00253-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-022-00253-3</ArticleId><ArticleId IdType="pmc">PMC9826760</ArticleId><ArticleId IdType="pubmed">36617565</ArticleId></ArticleIdList></Reference><Reference><Citation>Abani O., Abbas A., Abbas F., Abbas J., Abbas K., Abbas M., Abbasi S., Abbass H., Abbott A., Abbott A., et al. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400:359&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9333998</ArticleId><ArticleId IdType="pubmed">35908569</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconi V.C., Ramanan A.V., de Bono S., Kartman C.E., Krishnan V., Liao R., Piruzeli M.L.B., Alatorre-Alexander J., Pellegrini R.d.C., Estrada V., et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 2021;9:1407&#x2013;1418. doi: 10.1016/S2213-2600(21)00331-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00331-3</ArticleId><ArticleId IdType="pmc">PMC8409066</ArticleId><ArticleId IdType="pubmed">34480861</ArticleId></ArticleIdList></Reference><Reference><Citation>Abizanda P., Mayo J.M.C., Romero M.M., Zamora E.B.C., Sahuquillo M.T.T., Rizos L.R., S&#xe1;nchez-Jurado P.M., S&#xe1;nchez-Nievas G., Escolano C.C., Serrano A.O., et al. Baricitinib reduces 30-day mortality in older adults with moderate-to-severe COVID-19 pneumonia. J. Am. Geriatr. Soc. 2021;69:2752&#x2013;2758. doi: 10.1111/jgs.17357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.17357</ArticleId><ArticleId IdType="pmc">PMC8447356</ArticleId><ArticleId IdType="pubmed">34235720</ArticleId></ArticleIdList></Reference><Reference><Citation>Stebbing J., S&#xe1;nchez Nievas G., Falcone M., Youhanna S., Richardson P., Ottaviani S., Shen J.X., Sommerauer C., Tiseo G., Ghiadoni L., et al. JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Sci. Adv. 2021;7:eabe4724. doi: 10.1126/sciadv.abe4724.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abe4724</ArticleId><ArticleId IdType="pmc">PMC7775747</ArticleId><ArticleId IdType="pubmed">33187978</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe C.R., Tomashek K.M., Patterson T.F., Gomez C.A., Marconi V.C., Jain M.K., Yang O.O., Paules C.I., Palacios G.M.R., Grossberg R., et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): A randomised, double-blind, double placebo-controlled trial. Lancet Respir. Med. 2022;10:888&#x2013;899. doi: 10.1016/S2213-2600(22)00088-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00088-1</ArticleId><ArticleId IdType="pmc">PMC9126560</ArticleId><ArticleId IdType="pubmed">35617986</ArticleId></ArticleIdList></Reference><Reference><Citation>Troseid M., Arribas J.R., Assoumou L., Holten A.R., Poissy J., Terzic V., Mazzaferri F., Rodriguez-Bano J., Eustace J., Hites M., et al. Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): A randomised, double-blind, placebo-controlled phase 3 trial. Crit. Care. 2023;27:9. doi: 10.1186/s13054-022-04205-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04205-8</ArticleId><ArticleId IdType="pmc">PMC9830601</ArticleId><ArticleId IdType="pubmed">36627655</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferro F., La Rocca G., Elefante E., Italiano N., Moretti M., Talarico R., Pelati E., Valentini K., Baldini C., Mozzo R., et al. Baricitinib and Pulse Steroids Combination Treatment in Hyperinflammatory COVID-19: A Rheumatological Approach in the Intensive Care Unit. Int. J. Mol. Sci. 2024;25:7273. doi: 10.3390/ijms25137273.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms25137273</ArticleId><ArticleId IdType="pmc">PMC11242164</ArticleId><ArticleId IdType="pubmed">39000379</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezabakhsh A., Mojtahedi F., Tekantapeh S.T., Mahmoodpoor A., Ala A., Soleimanpour H. Therapeutic Impact of Tocilizumab in the Setting of Severe COVID-19; an Updated and Comprehensive Review on Current Evidence. Arch. Acad. Emerg. Med. 2024;12:e47. doi: 10.22037/aaem.v12i1.2217.</Citation><ArticleIdList><ArticleId IdType="doi">10.22037/aaem.v12i1.2217</ArticleId><ArticleId IdType="pmc">PMC11239185</ArticleId><ArticleId IdType="pubmed">38994467</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Wu Z., Li J.-W., Zhao H., Wang G.Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int. J. Antimicrob. Agents. 2020;55:105954. doi: 10.1016/j.ijantimicag.2020.105954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105954</ArticleId><ArticleId IdType="pmc">PMC7118634</ArticleId><ArticleId IdType="pubmed">32234467</ArticleId></ArticleIdList></Reference><Reference><Citation>Le R.Q., Li L., Yuan W., Shord S.S., Nie L., Habtemariam B.A., Przepiorka D., Farrell A.T., Pazdur R. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018;23:943&#x2013;947. doi: 10.1634/theoncologist.2018-0028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1634/theoncologist.2018-0028</ArticleId><ArticleId IdType="pmc">PMC6156173</ArticleId><ArticleId IdType="pubmed">29622697</ArticleId></ArticleIdList></Reference><Reference><Citation>Steuber T.D., Rosandich T., Cadwallader T., Steil L., Belk M., Yendrapalli U., Hassoun A., Edwards J. Dosing and Administration Strategies of Tocilizumab in Patients with COVID-19: A Retrospective Cohort Analysis. Ann. Pharmacother. 2023;58:391&#x2013;397. doi: 10.1177/10600280231190401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10600280231190401</ArticleId><ArticleId IdType="pubmed">37522616</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung E., Crass R.L., Jorgensen S.C.J., Raybardhan S., Langford B.J., Moore W.J., Rhodes N.J. Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. Clin. Pharmacokinet. 2021;61:155&#x2013;165. doi: 10.1007/s40262-021-01092-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40262-021-01092-0</ArticleId><ArticleId IdType="pmc">PMC8665708</ArticleId><ArticleId IdType="pubmed">34894345</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay M.Z., Poh C.M., R&#xe9;nia L., MacAry P.A., Ng L.F.P. The trinity of COVID-19: Immunity, inflammation and intervention. Nat. Rev. Immunol. 2020;20:363&#x2013;374. doi: 10.1038/s41577-020-0311-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0311-8</ArticleId><ArticleId IdType="pmc">PMC7187672</ArticleId><ArticleId IdType="pubmed">32346093</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637&#x2013;1645. doi: 10.1016/s0140-6736(21)00676-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(21)00676-0</ArticleId><ArticleId IdType="pmc">PMC8084355</ArticleId><ArticleId IdType="pubmed">33933206</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon A.C., Mouncey P.R., Al-Beidh F., Rowan K.M., Nichol A.D., Arabi Y.M., Annane D., Beane A., van Bentum-Puijk W., Berry L.R. Interleukin-6 Receptor Antagonists in Critically Ill Patients with COVID-19. N. Engl. J. Med. 2021;384:1491&#x2013;1502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953461</ArticleId><ArticleId IdType="pubmed">33631065</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkhateeb T., Stollings J.L., Sohn I., Liu D., Fleenor L.M., Ely E.W., Lahiri S. Tocilizumab is associated with reduced delirium and coma in critically ill patients with COVID-19. Sci. Rep. 2024;14:11738. doi: 10.1038/s41598-024-62505-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-62505-1</ArticleId><ArticleId IdType="pmc">PMC11111809</ArticleId><ArticleId IdType="pubmed">38778074</ArticleId></ArticleIdList></Reference><Reference><Citation>Rashid M.H., Sparrow N.A., Anwar F., Guidry G., Covarrubias A.E., Pang H., Bogguri C., Karumanchi S.A., Lahiri S. Interleukin-6 mediates delirium-like phenotypes in a murine model of urinary tract infection. J. Neuroinflamm. 2021;18:247. doi: 10.1186/s12974-021-02304-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02304-x</ArticleId><ArticleId IdType="pmc">PMC8554965</ArticleId><ArticleId IdType="pubmed">34711238</ArticleId></ArticleIdList></Reference><Reference><Citation>Anwar F., Sparrow N.A., Rashid M.H., Guidry G., Gezalian M.M., Ley E.J., Koronyo-Hamaoui M., Danovitch I., Ely E.W., Karumanchi S.A., et al. Systemic interleukin-6 inhibition ameliorates acute neuropsychiatric phenotypes in a murine model of acute lung injury. Crit. Care. 2022;26:274. doi: 10.1186/s13054-022-04159-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-04159-x</ArticleId><ArticleId IdType="pmc">PMC9469063</ArticleId><ArticleId IdType="pubmed">36100846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparrow N.A., Anwar F., Covarrubias A.E., Rajput P.S., Rashid M.H., Nisson P.L., Gezalian M.M., Toossi S., Ayodele M.O., Karumanchi S.A., et al. IL-6 Inhibition Reduces Neuronal Injury in a Murine Model of Ventilator-induced Lung Injury. Am. J. Respir. Cell Mol. Biol. 2021;65:403&#x2013;412. doi: 10.1165/rcmb.2021-0072OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2021-0072OC</ArticleId><ArticleId IdType="pmc">PMC8525200</ArticleId><ArticleId IdType="pubmed">34014798</ArticleId></ArticleIdList></Reference><Reference><Citation>Knorr J.P., Colomy V., Mauriello C.M., Ha S. Tocilizumab in patients with severe COVID-19: A single-center observational analysis. J. Med. Virol. 2020;92:2813&#x2013;2820. doi: 10.1002/jmv.26191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26191</ArticleId><ArticleId IdType="pmc">PMC7323415</ArticleId><ArticleId IdType="pubmed">32628003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hager D.N., Dinglas V.D., Subhas S., Rowden A.M., Neufeld K.J., Bienvenu O.J., Touradji P., Colantuoni E., Reddy D.R., Brower R.G., et al. Reducing Deep Sedation and Delirium in Acute Lung Injury Patients. Crit. Care Med. 2013;41:1435&#x2013;1442. doi: 10.1097/CCM.0b013e31827ca949.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31827ca949</ArticleId><ArticleId IdType="pubmed">23507716</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.H., Patel B., Podel B., Szablea M.E., Shaaban H.S., Guron G., Slim J. Tocilizumab and Thromboembolism in COVID-19: A Retrospective Hospital-Based Cohort Analysis. Cureus. 2021;13:e15208. doi: 10.7759/cureus.15208.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.15208</ArticleId><ArticleId IdType="pmc">PMC8220488</ArticleId><ArticleId IdType="pubmed">34178527</ArticleId></ArticleIdList></Reference><Reference><Citation>Hafez W., Ziade M.A., Arya A., Saleh H., Abdelshakor M., Alla O.F., Agrawal P., Ali S., Rao S.R., Gupta S., et al. Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study. Antibiotics. 2022;11:241. doi: 10.3390/antibiotics11020241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics11020241</ArticleId><ArticleId IdType="pmc">PMC8868075</ArticleId><ArticleId IdType="pubmed">35203844</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosas I.O., Br&#xe4;u N., Waters M., Go R.C., Hunter B.D., Bhagani S., Skiest D., Aziz M.S., Cooper N., Douglas I.S., et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N. Engl. J. Med. 2021;384:1503&#x2013;1516. doi: 10.1056/NEJMoa2028700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028700</ArticleId><ArticleId IdType="pmc">PMC7953459</ArticleId><ArticleId IdType="pubmed">33631066</ArticleId></ArticleIdList></Reference><Reference><Citation>Aljuhani O., Al Sulaiman K., Korayem G.B., Altebainawi A.F., Alsohimi S., Alqahtani R., Alfaifi S., Alharbi A., AlKhayrat A., Hattan A., et al. The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: A multicenter, cohort study. Sci. Rep. 2024;14:3037. doi: 10.1038/s41598-024-53087-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-53087-z</ArticleId><ArticleId IdType="pmc">PMC10847412</ArticleId><ArticleId IdType="pubmed">38321099</ArticleId></ArticleIdList></Reference><Reference><Citation>Guaraldi G., Meschiari M., Cozzi-Lepri A., Milic J., Tonelli R., Menozzi M., Franceschini E., Cuomo G., Orlando G., Borghi V., et al. Tocilizumab in patients with severe COVID-19: A retrospective cohort study. Lancet Rheumatol. 2020;2:e474&#x2013;e484. doi: 10.1016/S2665-9913(20)30173-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30173-9</ArticleId><ArticleId IdType="pmc">PMC7314456</ArticleId><ArticleId IdType="pubmed">32835257</ArticleId></ArticleIdList></Reference><Reference><Citation>Hermine O., Mariette X., Tharaux P.-L., Resche-Rigon M., Porcher R., Ravaud P., Bureau S., Dougados M., Tibi A., CORIMUNO-19 Collaborative Group et al. Effect of Tocilizumab vs Usual Care in Adults Hospitalized with COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern. Med. 2021;181:32&#x2013;40. doi: 10.1001/jamainternmed.2020.6820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.6820</ArticleId><ArticleId IdType="pmc">PMC7577198</ArticleId><ArticleId IdType="pubmed">33080017</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone J.H., Frigault M.J., Serling-Boyd N.J., Fernandes A.D., Harvey L., Foulkes A.S., Horick N.K., Healy B.C., Shah R., Bensaci A.M., et al. Efficacy of Tocilizumab in Patients Hospitalized with COVID-19. N. Engl. J. Med. 2020;383:2333&#x2013;2344. doi: 10.1056/NEJMoa2028836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028836</ArticleId><ArticleId IdType="pmc">PMC7646626</ArticleId><ArticleId IdType="pubmed">33085857</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu D.-E., Ou T.-Y., Kang J.-W., Ong J.Y., Chen I.-J., Lee C.-H., Lee M.-C. The association between tocilizumab and the secondary bloodstream infection maybe nonsignificant in hospitalized patients with SARS-CoV-2 infection: A cohort study. J. Microbiol. Immunol. Infect. 2024;57:38&#x2013;47. doi: 10.1016/j.jmii.2023.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2023.10.011</ArticleId><ArticleId IdType="pubmed">37951803</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Liang Q., Chen F., Zheng J., Chen Y., Chen Z., Li R., Li X. Immune-Cell-Based Therapy for COVID-19: Current Status. Viruses. 2023;15:2148. doi: 10.3390/v15112148.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15112148</ArticleId><ArticleId IdType="pmc">PMC10674523</ArticleId><ArticleId IdType="pubmed">38005826</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xe1;llay K., Kassa C., R&#xe9;ti M., Kar&#xe1;szi &#xc9;., Sink&#xf3; J., Goda V., Str&#xe9;hn A., Csord&#xe1;s K., Horv&#xe1;th O., Szederjesi A., et al. Early Experience with CliniMACS Prodigy CCS (IFN-gamma) System in Selection of Virus-specific T Cells from Third-party Donors for Pediatric Patients with Severe Viral Infections after Hematopoietic Stem Cell Transplantation. J. Immunother. 2018;41:158&#x2013;163. doi: 10.1097/CJI.0000000000000197.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CJI.0000000000000197</ArticleId><ArticleId IdType="pubmed">29239916</ArticleId></ArticleIdList></Reference><Reference><Citation>Naik S., Nicholas S.K., Martinez C.A., Leen A.M., Hanley P.J., Gottschalk S.M., Rooney C.M., Hanson I.C., Krance R.A., Shpall E.J., et al. Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J. Allergy Clin. Immunol. 2016;137:1498&#x2013;1505. doi: 10.1016/j.jaci.2015.12.1311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2015.12.1311</ArticleId><ArticleId IdType="pmc">PMC4860050</ArticleId><ArticleId IdType="pubmed">26920464</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu Y., Milner J., Lamb M., Maryamchik E., Rigot O., Ayello J., Harrison L., Shaw R., Behbehani G.K., Mardis E.R., et al. Manufacture and Characterization of Good Manufacturing Practice-Compliant SARS-CoV-2 Cytotoxic T Lymphocytes. J. Infect. Dis. 2022;227:788&#x2013;799. doi: 10.1093/infdis/jiac500.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac500</ArticleId><ArticleId IdType="pubmed">36583990</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleakley M.M., Gooley T.A., Hilzinger B., Riddell S.R., Shlomchik W.D. Na&#xef;Ve T Cell Depletion of PBSC Grafts Results in Very Low Rates of Chronic Gvhd and High Survival. Blood. 2016;128:668. doi: 10.1182/blood.V128.22.668.668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V128.22.668.668</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan J.M., Mateus J., Kato Y., Hastie K.M., Yu E.D., Faliti C.E., Grifoni A., Ramirez S.I., Haupt S., Frazier A., et al. Immunological Memory to SARS-CoV-2 Assessed for Up to 8 Months after Infection. Science. 2021;371:eabf4063. doi: 10.1126/science.abf4063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf4063</ArticleId><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Papadopoulou A., Karavalakis G., Papadopoulou E., Xochelli A., Bousiou Z., Vogiatzoglou A., Papayanni P.G., Georgakopoulou A., Giannaki M., Stavridou F., et al. SARS-CoV-2-specific T cell therapy for severe COVID-19: A randomized phase 1/2 trial. Nat. Med. 2023;29:2019&#x2013;2029. doi: 10.1038/s41591-023-02480-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02480-8</ArticleId><ArticleId IdType="pubmed">37460756</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreras C., Hern&#xe1;ndez-Blanco C., Mart&#xed;n-Quir&#xf3;s A., Al-Akioui-Sanz K., Mora-Rillo M., Ib&#xe1;&#xf1;ez F., D&#xed;az-Almir&#xf3;n M., Cano-Ochando J., Lozano-Ojalvo D., Jim&#xe9;nez-Gonz&#xe1;lez M., et al. Results of phase 2 randomized multi-center study to evaluate the safety and efficacy of infusion of memory T cells as adoptive therapy in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia and/or lymphopenia (RELEASE NCT04578210) Cytotherapy. 2024;26:25&#x2013;35. doi: 10.1016/j.jcyt.2023.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcyt.2023.10.002</ArticleId><ArticleId IdType="pubmed">37897472</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong R.Y.L., Seah V.X.F., Chong C.Y., Thoon K.C., Tan N.W.H., Li J., Nadua K.D., Soh S.Y., Seng M.S.-F., Pham T.N.A., et al. A cohort study of COVID-19 infection in pediatric oncology patients plus the utility and safety of remdesivir treatment. Acta Oncol. 2023;62:53&#x2013;57. doi: 10.1080/0284186X.2023.2169079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0284186X.2023.2169079</ArticleId><ArticleId IdType="pubmed">36661030</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarke A., Coelho C.H., Zhang Z., Dan J.M., Yu E.D., Methot N., Bloom N.I., Goodwin B., Phillips E., Mallal S., et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell. 2022;185:847&#x2013;859. doi: 10.1016/j.cell.2022.01.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.015</ArticleId><ArticleId IdType="pmc">PMC8784649</ArticleId><ArticleId IdType="pubmed">35139340</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavvar M., Yahyapoor A., Baghdadi H., Zargaran S., Assadiasl S., Abdolmohammadi K., Abooei A.H., Sattarian M.R., JalaliFarahani M., Zarei N., et al. COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches. Int. Immunopharmacol. 2022;107:108655. doi: 10.1016/j.intimp.2022.108655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.108655</ArticleId><ArticleId IdType="pmc">PMC8872837</ArticleId><ArticleId IdType="pubmed">35248946</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Jiang X., Dai X., Li B. The Dynamic Role of FOXP3+ Tregs and Their Potential Therapeutic Applications during SARS-CoV-2 Infection. Front. Immunol. 2022;13:916411. doi: 10.3389/fimmu.2022.916411.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.916411</ArticleId><ArticleId IdType="pmc">PMC9305488</ArticleId><ArticleId IdType="pubmed">35874688</ArticleId></ArticleIdList></Reference><Reference><Citation>Fransson M., Piras E., Burman J., Nilsson B., Essand M., Lu B., Harris R.A., Magnusson P.U., Brittebo E., Loskog A.S. CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J. Neuroinflamm. 2012;9:112. doi: 10.1186/1742-2094-9-112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-112</ArticleId><ArticleId IdType="pmc">PMC3403996</ArticleId><ArticleId IdType="pubmed">22647574</ArticleId></ArticleIdList></Reference><Reference><Citation>Blat D., Zigmond E., Alteber Z., Waks T., Eshhar Z. Suppression of Murine Colitis and its Associated Cancer by Carcinoembryonic Antigen-Specific Regulatory T Cells. Mol. Ther. 2014;22:1018&#x2013;1028. doi: 10.1038/mt.2014.41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2014.41</ArticleId><ArticleId IdType="pmc">PMC4015241</ArticleId><ArticleId IdType="pubmed">24686242</ArticleId></ArticleIdList></Reference><Reference><Citation>Skuljec J., Chmielewski M., Happle C., Habener A., Busse M., Abken H., Hansen G. Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma. Front. Immunol. 2017;8:1125. doi: 10.3389/fimmu.2017.01125.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01125</ArticleId><ArticleId IdType="pmc">PMC5600908</ArticleId><ArticleId IdType="pubmed">28955341</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan T., Zhou X., Zhou W., Lin H. Regulatory T cell and macrophage crosstalk in acute lung injury: Future perspectives. Cell Death Discov. 2023;9:9. doi: 10.1038/s41420-023-01310-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41420-023-01310-7</ArticleId><ArticleId IdType="pmc">PMC9841501</ArticleId><ArticleId IdType="pubmed">36646692</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Yang X.O. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J. Microbiol. Immunol. Infect. 2020;53:368&#x2013;370. doi: 10.1016/j.jmii.2020.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2020.03.005</ArticleId><ArticleId IdType="pmc">PMC7156211</ArticleId><ArticleId IdType="pubmed">32205092</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#xe7;alves-Pereira M.H., Santiago L., Ravetti C.G., Vassallo P.F., de Andrade M.V.M., Vieira M.S., Oliveira F.d.F.S.d., Carobin N.V., Li G., Sabino A.d.P., et al. Dysfunctional phenotype of systemic and pulmonary regulatory T cells associate with lethal COVID-19 cases. Immunology. 2022;168:684&#x2013;696. doi: 10.1111/imm.13603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13603</ArticleId><ArticleId IdType="pmc">PMC9877711</ArticleId><ArticleId IdType="pubmed">36349514</ArticleId></ArticleIdList></Reference><Reference><Citation>Khesht A.M., Karpisheh V., Saeed B.Q., Zekiy A.O., Yapanto L.M., Afjadi M.N., Aksoun M., Esfahani M.N., Aghakhani F., Movahed M., et al. Different T cell related immunological profiles in COVID-19 patients compared to healthy controls. Int. Immunopharmacol. 2021;97:107828. doi: 10.1016/j.intimp.2021.107828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107828</ArticleId><ArticleId IdType="pmc">PMC8162824</ArticleId><ArticleId IdType="pubmed">34091116</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladstone D.E., D&#x2019;Alessio F.R., Howard C., Lyu M.-A., Mock J.R., Gibbs K.W., Abrams D., Huang M., Zeng K., Herlihy J.P., et al. Randomized, double-blinded, placebo-controlled trial of allogeneic cord blood T-regulatory cells for treatment of COVID-19 ARDS. Blood Adv. 2023;7:3075&#x2013;3079. doi: 10.1182/bloodadvances.2022009619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022009619</ArticleId><ArticleId IdType="pmc">PMC10043947</ArticleId><ArticleId IdType="pubmed">36961352</ArticleId></ArticleIdList></Reference><Reference><Citation>Buitrago-Molina L.E., Pietrek J., Noyan F., Schlue J., Manns M.P., Wedemeyer H., Hardtke-Wolenski M., Jaeckel E. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. J. Autoimmun. 2020;117:102591. doi: 10.1016/j.jaut.2020.102591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2020.102591</ArticleId><ArticleId IdType="pubmed">33387980</ArticleId></ArticleIdList></Reference><Reference><Citation>Humrich J.Y., Riemekasten G. Restoring regulation&#x2014;IL-2 therapy in systemic lupus erythematosus. Expert Rev. Clin. Immunol. 2016;12:1153&#x2013;1160. doi: 10.1080/1744666X.2016.1199957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2016.1199957</ArticleId><ArticleId IdType="pubmed">27283871</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyman O., Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 2012;12:180&#x2013;190. doi: 10.1038/nri3156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3156</ArticleId><ArticleId IdType="pubmed">22343569</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M., Rabaan A.A., Alwarthan S., Alhajri M., Halwani M.A., Alshengeti A., Najim M.A., Alwashmi A.S.S., Alshehri A.A., Alshamrani S.A., et al. Regulatory T Cells (Tregs) and COVID-19: Unveiling the Mechanisms, and Therapeutic Potentialities with a Special Focus on Long COVID. Vaccines. 2023;11:699. doi: 10.3390/vaccines11030699.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11030699</ArticleId><ArticleId IdType="pmc">PMC10059134</ArticleId><ArticleId IdType="pubmed">36992283</ArticleId></ArticleIdList></Reference><Reference><Citation>Alavi-Dana S.M.M., Gholami Y., Meghdadi M., Fadaei M.S., Askari V.R. Mesenchymal stem cell therapy for COVID-19 infection. Inflammopharmacology. 2023;32:319&#x2013;334. doi: 10.1007/s10787-023-01394-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-023-01394-8</ArticleId><ArticleId IdType="pubmed">38117433</ArticleId></ArticleIdList></Reference><Reference><Citation>Cipriani P., Carubbi F., Liakouli V., Marrelli A., Perricone C., Perricone R., Alesse E., Giacomelli R. Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. Autoimmun. Rev. 2013;12:709&#x2013;716. doi: 10.1016/j.autrev.2012.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2012.10.004</ArticleId><ArticleId IdType="pubmed">23183379</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y., Chen X., Liu Q., Zhang X., Huang K., Liu L., Li H., Zhou M., Huang F., Fan Z., et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia. 2014;29:636&#x2013;646. doi: 10.1038/leu.2014.225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/leu.2014.225</ArticleId><ArticleId IdType="pubmed">25034146</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J.-Y., Lee Y.-K., Ran X., Liao S.-Y., Yang J., Au K.-W., Lai W.-H., Esteban M.A., Tse H.-F. Generation of Induced Cardiospheres via Reprogramming of Skin Fibroblasts for Myocardial Regeneration. Stem Cells. 2016;34:2693&#x2013;2706. doi: 10.1002/stem.2438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.2438</ArticleId><ArticleId IdType="pubmed">27333945</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh M., Vaezi A.A., Aliannejad R., Sohrabpour A.A., Kiaei S.Z.F., Shadnoush M., Siavashi V., Aghaghazvini L., Khoundabi B., Abdoli S., et al. Cell therapy in patients with COVID-19 using Wharton&#x2019;s jelly mesenchymal stem cells: A phase 1 clinical trial. Stem Cell Res. Ther. 2021;12:410. doi: 10.1186/s13287-021-02483-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-021-02483-7</ArticleId><ArticleId IdType="pmc">PMC8283394</ArticleId><ArticleId IdType="pubmed">34271988</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta V., Sengupta S., Lazo A., Woods P., Nolan A., Bremer N. Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020;29:747&#x2013;754. doi: 10.1089/scd.2020.0080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/scd.2020.0080</ArticleId><ArticleId IdType="pmc">PMC7310206</ArticleId><ArticleId IdType="pubmed">32380908</ArticleId></ArticleIdList></Reference><Reference><Citation>Adas G., Cukurova Z., Yasar K.K., Yilmaz R., Isiksacan N., Kasapoglu P., Yesilbag Z., Koyuncu I., Karaoz E. The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial. Cell Transplant. 2021;30:096368972110249. doi: 10.1177/09636897211024942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09636897211024942</ArticleId><ArticleId IdType="pmc">PMC8243094</ArticleId><ArticleId IdType="pubmed">34180719</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilogo I.H., Aditianingsih D., Sugiarto A., Burhan E., Damayanti T., Sitompul P.A., Mariana N., Antarianto R.D., Liem I.K., Kispa T., et al. Umbilical Cord Mesenchymal Stromal Cells as Critical COVID-19 Adjuvant Therapy: A Randomized Controlled Trial. Stem Cells Transl. Med. 2021;10:1279&#x2013;1287. doi: 10.1002/sctm.21-0046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sctm.21-0046</ArticleId><ArticleId IdType="pmc">PMC8242692</ArticleId><ArticleId IdType="pubmed">34102020</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringden O., Roshandel E., Pirsalehi A., Kazemi S., Sankanian G., Majidi M., Salimi M., Aghdami N., Sadrosadat H., Kochaksaraei S.S., et al. Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells. Biol. Blood Marrow Transplant. 2022;28:S222. doi: 10.1016/S2666-6367(22)00440-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-6367(22)00440-7</ArticleId><ArticleId IdType="pmc">PMC8581334</ArticleId><ArticleId IdType="pubmed">34632708</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkhad N.K., Sedaghat A., Reihani H., Moghadam A.A., Moghadam A.B., Ghaebi N.K., Khodadoust M.A., Ganjali R., Tafreshian A.R., Tavakol-Afshari J. Mesenchymal stromal cell therapy for COVID-19-induced ARDS patients: A successful phase 1, control-placebo group, clinical trial. Stem Cell Res. Ther. 2022;13:283. doi: 10.1186/s13287-022-02920-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-022-02920-1</ArticleId><ArticleId IdType="pmc">PMC9241239</ArticleId><ArticleId IdType="pubmed">35765103</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsel A., Hauw-Berlemont C., Mebarki M., Heming N., Mayaux J., Tchoumba O.N., Diehl J.-L., Demoule A., Annane D., Marois C., et al. Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: A multicenter randomized double-blind trial. Crit. Care. 2022;26:48. doi: 10.1186/s13054-022-03930-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-022-03930-4</ArticleId><ArticleId IdType="pmc">PMC8860258</ArticleId><ArticleId IdType="pubmed">35189925</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi L., Zheng Y., Cheng Z., Ji N., Niu C., Wang Y., Huang T., Li R., Huang M., Chen X., et al. One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment. Stem Cell Res. Ther. 2022;13:321. doi: 10.1186/s13287-022-02972-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-022-02972-3</ArticleId><ArticleId IdType="pmc">PMC9288258</ArticleId><ArticleId IdType="pubmed">35842684</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T.-T., Li T.-T., Zhang B., Zhang B., Fang H., Fang H., Shi M., Shi M., Yao W.-Q., Yao W.-Q., et al. Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial. eBioMedicine. 2023;92:104600. doi: 10.1016/j.ebiom.2023.104600.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104600</ArticleId><ArticleId IdType="pmc">PMC10161678</ArticleId><ArticleId IdType="pubmed">37149930</ArticleId></ArticleIdList></Reference><Reference><Citation>Yudintceva N., Mikhailova N., Fedorov V., Samochernych K., Vinogradova T., Muraviov A., Shevtsov M. Mesenchymal Stem Cells and MSCs-Derived Extracellular Vesicles in Infectious Diseases: From Basic Research to Clinical Practice. Bioengineering. 2022;9:662. doi: 10.3390/bioengineering9110662.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bioengineering9110662</ArticleId><ArticleId IdType="pmc">PMC9687734</ArticleId><ArticleId IdType="pubmed">36354573</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukomska B., Stanaszek L., Zuba-Surma E., Legosz P., Sarzynska S., Drela K. Challenges and Controversies in Human Mesenchymal Stem Cell Therapy. Stem Cells Int. 2019;2019:9628536. doi: 10.1155/2019/9628536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/9628536</ArticleId><ArticleId IdType="pmc">PMC6481040</ArticleId><ArticleId IdType="pubmed">31093291</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., P&#xe9;rez Marc G., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunkle L.M., Kotloff K.L., Gay C.L., &#xc1;&#xf1;ez G., Adelglass J.M., Barrat Hern&#xe1;ndez A.Q., Harper W.L., Duncanson D.M., McArthur M.A., Florescu D.F., et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N. Engl. J. Med. 2022;386:531&#x2013;543. doi: 10.1056/NEJMoa2116185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2116185</ArticleId><ArticleId IdType="pmc">PMC8693692</ArticleId><ArticleId IdType="pubmed">34910859</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert P.B., Montefiori D.C., McDermott A.B., Fong Y., Benkeser D., Deng W., Zhou H., Houchens C.R., Martins K., Jayashankar L., et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375:43&#x2013;50. doi: 10.1126/science.abm3425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm3425</ArticleId><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier A.-R.Y., Yu J., McMahan K., Liu J., Chandrashekar A., Maron J.S., Atyeo C., Martinez D.R., Ansel J.L., Aguayo R., et al. Differential kinetics of immune responses elicited by COVID-19 vaccines. N. Engl. J. Med. 2021;385:2010&#x2013;2012. doi: 10.1056/NEJMc2115596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2115596</ArticleId><ArticleId IdType="pmc">PMC8531985</ArticleId><ArticleId IdType="pubmed">34648703</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S., Yu Y., Xu Y., Jian F., Song W., Yisimayi A., Wang P., Wang J., Liu J., Yu L., et al. Fast evolution of SARS-CoV-2 BA. 2.86 to JN. 1 under heavy immune pressure. Lancet Infect. Dis. 2024;24:e70&#x2013;e72. doi: 10.1016/S1473-3099(23)00744-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00744-2</ArticleId><ArticleId IdType="pubmed">38109919</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Guo Y., Bowen A., Mellis I.A., Valdez R., Gherasim C., Gordon A., Liu L., Ho D.D. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024;32:315&#x2013;321. doi: 10.1016/j.chom.2024.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2024.01.014</ArticleId><ArticleId IdType="pmc">PMC10948033</ArticleId><ArticleId IdType="pubmed">38377995</ArticleId></ArticleIdList></Reference><Reference><Citation>Kojima N., Adams K., Self W.H., Gaglani M., McNeal T., Ghamande S., Steingrub J.S., Shapiro N.I., Duggal A., Busse L.W., et al. Changing severity and epidemiology of adults hospitalized with coronavirus disease 2019 (COVID-19) in the United States after introduction of COVID-19 vaccines, March 2021&#x2013;August 2022. Clin. Infect. Dis. 2023;77:547&#x2013;557. doi: 10.1093/cid/ciad276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad276</ArticleId><ArticleId IdType="pmc">PMC10526883</ArticleId><ArticleId IdType="pubmed">37255285</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde M.W., Self W.H., Adams K., Gaglani M., Ginde A.A., McNeal T., Ghamande S., Douin D.J., Talbot H.K., Casey J.D., et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021;326:2043&#x2013;2054. doi: 10.1001/jama.2021.19499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.19499</ArticleId><ArticleId IdType="pmc">PMC8569602</ArticleId><ArticleId IdType="pubmed">34734975</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzpatrick M.C., Galvani A.P. Optimizing age-specific vaccination. Science. 2021;371:890&#x2013;891. doi: 10.1126/science.abg2334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg2334</ArticleId><ArticleId IdType="pubmed">33479122</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaoui S., Foguem C., Tchuente D., Fosso-Wamba S., Kamsu-Foguem B. The viability of supply chains with interpretable learning systems: The case of COVID-19 vaccine deliveries. Glob. J. Flex. Syst. Manag. 2023;24:633&#x2013;657. doi: 10.1007/s40171-023-00357-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40171-023-00357-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavi, the Vaccine Alliance  COVAX Explained. [Online]. Gavi, the Vaccine Alliance. 2023.  [(accessed on 30 June 2024)].  Available online:  https://www.gavi.org/vaccineswork/covax-explained.</Citation></Reference><Reference><Citation>World Health Organization  COVID-19 Vaccinations Shift to Regular Immunization as COVAX Draws to a Close. [Online]. World Health Organization. 2023.  [(accessed on 30 June 2024)].  Available online:  https://www.who.int/news/item/19-12-2023-covid-19-vaccinations-shift-to-regular-immunization-as-covax-draws-to-a-close.</Citation></Reference><Reference><Citation>Sign&#xa2; L. Strategies for Effective Health Care for Africa in the Fourth Industrial Revolution, Bridging the Gap between the Promise and Delivery. [Online] 2021.  [(accessed on 2 July 2024)].  Available online:  https://www.brookings.edu/wp-content/uploads/2021/10/Strategies-for-effective-health-care-delivery-in-Africa_FINAL.pdf.</Citation></Reference><Reference><Citation>Hierink F., Okiro E.A., Flahault A., Ray N. The winding road to health: A systematic scoping review on the effect of geographical accessibility to health care on infectious diseases in low- and middle-income countries. PLoS ONE. 2021;16:e0244921. doi: 10.1371/journal.pone.0244921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0244921</ArticleId><ArticleId IdType="pmc">PMC7781385</ArticleId><ArticleId IdType="pubmed">33395431</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Aditus  Rwanda Welcomes Africa&#x2019;s First Mobile Vaccine-Production Units. Med Aditus. [Online] 2023.  [(accessed on 30 June 2024)].  Available online:  https://medaditus.org/news-articles/rwanda-welcomes-africas-first-mobile-vaccine-production-units/</Citation></Reference><Reference><Citation>Masresha B., Ruiz M.A.S., Atuhebwe P., Mihigo R. The first year of COVID-19 vaccine roll-out in Africa: Challenges and lessons learned. Pan Afr. Med. J. 2022;41:2. doi: 10.11604/pamj.supp.2022.41.2.33686.</Citation><ArticleIdList><ArticleId IdType="doi">10.11604/pamj.supp.2022.41.2.33686</ArticleId><ArticleId IdType="pmc">PMC9474932</ArticleId><ArticleId IdType="pubmed">36159028</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel A.B., Kanevsky I., Che Y., Swanson K.A., Muik A., Vormehr M., Kranz L.M., Walzer K.C., Hein S., G&#xfc;ler A., et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021;592:283&#x2013;289. doi: 10.1038/s41586-021-03275-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03275-y</ArticleId><ArticleId IdType="pubmed">33524990</ArticleId></ArticleIdList></Reference><Reference><Citation>Muik A., Lui B.G., Wallisch A.-K., Bacher M., M&#xfc;hl J., Reinholz J., Ozhelvaci O., Beckmann N., Garcia R.d.l.C.G., Poran A., et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine&#x2013;elicited human sera. Science. 2022;375:678&#x2013;680. doi: 10.1126/science.abn7591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn7591</ArticleId><ArticleId IdType="pmc">PMC9836206</ArticleId><ArticleId IdType="pubmed">35040667</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh E.E., Frenck R.W., Jr., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. Safety and Immunogenicity of Two RNA-Based COVID-19 Vaccine Candidates. N. Engl. J. Med. 2020;383:2439&#x2013;2450. doi: 10.1056/NEJMoa2027906.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2027906</ArticleId><ArticleId IdType="pmc">PMC7583697</ArticleId><ArticleId IdType="pubmed">33053279</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U., Muik A., Derhovanessian E., Vogler I., Kranz L.M., Vormehr M., Baum A., Pascal K., Quandt J., Maurus D., et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature. 2020;586:594&#x2013;599. doi: 10.1038/s41586-020-2814-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2814-7</ArticleId><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas S.J., Moreira E.D., Jr., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., P&#xe9;rez Marc G., Polack F.P., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N. Engl. J. Med. 2021;385:1761&#x2013;1773. doi: 10.1056/NEJMoa2110345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110345</ArticleId><ArticleId IdType="pmc">PMC8461570</ArticleId><ArticleId IdType="pubmed">34525277</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Tang P., Hasan M.R., AlMukdad S., Yassine H.M., Benslimane F.M., Al Khatib H.A., Coyle P., Ayoub H.H., Al Kanaani Z., et al. Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N. Engl. J. Med. 2021;385:e83. doi: 10.1056/NEJMoa2114114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114114</ArticleId><ArticleId IdType="pmc">PMC8522799</ArticleId><ArticleId IdType="pubmed">34614327</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Slezak J.M., Fischer H., Hong V., Ackerson B.K., Ranasinghe O.N., Frankland T.B., Ogun O.A., Zamparo J.M., Gray S., et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study. Lancet. 2021;398:1407&#x2013;1416. doi: 10.1016/S0140-6736(21)02183-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02183-8</ArticleId><ArticleId IdType="pmc">PMC8489881</ArticleId><ArticleId IdType="pubmed">34619098</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang P., Hasan M.R., Chemaitelly H., Yassine H.M., Benslimane F.M., Al Khatib H.A., AlMukdad S., Coyle P., Ayoub H.H., Al Kanaani Z., et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat. Med. 2021;27:2136&#x2013;2143. doi: 10.1038/s41591-021-01583-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01583-4</ArticleId><ArticleId IdType="pubmed">34728831</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad L.J., Chemaitelly H., Butt A.A. Effectiveness of the BNT162b2 COVID-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N. Engl. J. Med. 2021;385:187&#x2013;189. doi: 10.1056/NEJMc2104974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2104974</ArticleId><ArticleId IdType="pmc">PMC8117967</ArticleId><ArticleId IdType="pubmed">33951357</ArticleId></ArticleIdList></Reference><Reference><Citation>Abu-Raddad L.J., Chemaitelly H., Ayoub H.H., AlMukdad S., Yassine H.M., Al-Khatib H.A., Smatti M.K., Tang P., Hasan M.R., Coyle P., et al. Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar. N. Engl. J. Med. 2022;386:1804&#x2013;1816. doi: 10.1056/NEJMoa2200797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200797</ArticleId><ArticleId IdType="pmc">PMC8929389</ArticleId><ArticleId IdType="pubmed">35263534</ArticleId></ArticleIdList></Reference><Reference><Citation>Veneti L., Berild J.D., Watle S.V., Starrfelt J., Greve-Isdahl M., Langlete P., B&#xf8;&#xe5;s H., Bragstad K., Hungnes O., Meijerink H. Effectiveness of BNT162b2 vaccine against SARS-CoV-2 Delta and Omicron infection in adolescents, Norway, August 2021 to January 2022. Int. J. Infect. Dis. 2023;130:182&#x2013;188. doi: 10.1016/j.ijid.2023.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.03.004</ArticleId><ArticleId IdType="pmc">PMC9991321</ArticleId><ArticleId IdType="pubmed">36893942</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatzilena A., Hyams C., Challen R., Marlow R., King J., Adegbite D., Kinney J., Clout M., Maskell N., Oliver J., et al. Effectiveness of BNT162b2 COVID-19 vaccination in prevention of hospitalisations and severe disease in adults with SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant between June 2021 and July 2022: A prospective test negative case&#x2013;control study. Lancet Reg. Health&#x2014;Eur. 2022;25:100552. doi: 10.1016/j.lanepe.2022.100552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100552</ArticleId><ArticleId IdType="pmc">PMC9728025</ArticleId><ArticleId IdType="pubmed">36506791</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira E.D., Kitchin N., Xu X., Dychter S.S., Lockhart S., Gurtman A., Perez J.L., Zerbini C., Dever M.E., Jennings T.W., et al. Safety and Efficacy of a Third Dose of BNT162b2 COVID-19 Vaccine. N. Engl. J. Med. 2022;386:1910&#x2013;1921. doi: 10.1056/NEJMoa2200674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200674</ArticleId><ArticleId IdType="pmc">PMC9006787</ArticleId><ArticleId IdType="pubmed">35320659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pather S., Muik A., Rizzi R., Mensa F. Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: The early Omicron era. Expert Rev. Vaccines. 2023;22:650&#x2013;661. doi: 10.1080/14760584.2023.2232851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14760584.2023.2232851</ArticleId><ArticleId IdType="pubmed">37417000</ArticleId></ArticleIdList></Reference><Reference><Citation>US Centers for Disease Control and Prevention  Stay Up to Date with COVID-19 Vaccines.  [(accessed on 7 July 2024)];2024  Available online:  https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html#UTD.</Citation></Reference><Reference><Citation>Winokur P., Gayed J., Fitz-Patrick D., Thomas S.J., Diya O., Lockhart S., Xu X., Zhang Y., Bangad V., Schwartz H.I., et al. Bivalent Omicron BA.1&#x2013;Adapted BNT162b2 Booster in Adults Older than 55 Years. N. Engl. J. Med. 2023;388:214&#x2013;227. doi: 10.1056/NEJMoa2213082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2213082</ArticleId><ArticleId IdType="pmc">PMC9933930</ArticleId><ArticleId IdType="pubmed">36652353</ArticleId></ArticleIdList></Reference><Reference><Citation>Muik A., Lui B.G., Bacher M., Wallisch A.-K., Toker A., Couto C.I.C., G&#xfc;ler A., Mampilli V., Schmitt G.J., Mottl J., et al. Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice. Sci. Immunol. 2022;7:eade9888. doi: 10.1126/sciimmunol.ade9888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.ade9888</ArticleId><ArticleId IdType="pmc">PMC9765452</ArticleId><ArticleId IdType="pubmed">36378074</ArticleId></ArticleIdList></Reference><Reference><Citation>Muik A., Lui B.G., Bacher M., Wallisch A.-K., Toker A., Finlayson A., Kr&#xfc;ger K., Ozhelvaci O., Grikscheit K., Hoehl S., et al. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5. Sci. Immunol. 2022;7:eade2283. doi: 10.1126/sciimmunol.ade2283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.ade2283</ArticleId><ArticleId IdType="pmc">PMC9529054</ArticleId><ArticleId IdType="pubmed">36125366</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou J., Kurhade C., Patel S., Kitchin N., Tompkins K., Cutler M., Cooper D., Yang Q., Cai H., Muik A., et al. Neutralization of BA.4&#x2013;BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine. N. Engl. J. Med. 2023;388:854&#x2013;857. doi: 10.1056/NEJMc2214916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2214916</ArticleId><ArticleId IdType="pmc">PMC9891359</ArticleId><ArticleId IdType="pubmed">36734885</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersson N.W., Thiesson E.M., Baum U., Pihlstr&#xf6;m N., Starrfelt J., Faksov&#xe1; K., Poukka E., Meijerink H., Ljung R., Hviid A. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged &#x2265; 50 years in Nordic countries: Nationwide cohort study. BMJ. 2023;382:e075286. doi: 10.1136/bmj-2022-075286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-075286</ArticleId><ArticleId IdType="pmc">PMC10364194</ArticleId><ArticleId IdType="pubmed">37491022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S.Y., Slezak J.M., Puzniak L., Hong V., Frankland T.B., Ackerson B.K., Xie F., Takhar H., Ogun O.A., Simmons S., et al. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: A test-negative case&#x2013;control study. Lancet Respir. Med. 2023;11:1089&#x2013;1100. doi: 10.1016/S2213-2600(23)00306-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00306-5</ArticleId><ArticleId IdType="pubmed">37898148</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurhade C., Zou J., Xia H., Liu M., Chang H.C., Ren P., Xie X., Shi P. Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster. Nat. Med. 2022;29:344&#x2013;347. doi: 10.1038/s41591-022-02162-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-02162-x</ArticleId><ArticleId IdType="pubmed">36473500</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayed J., Bangad V., Xu X., Mensa F., Cutler M., T&#xfc;reci &#xd6;., &#x15e;ahin U., Modjarrad K., Swanson K.A., Anderson A.S., et al. Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial. Vaccines. 2024;12:734. doi: 10.3390/vaccines12070734.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12070734</ArticleId><ArticleId IdType="pmc">PMC11281410</ArticleId><ArticleId IdType="pubmed">39066372</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayed J., Diya O., Lowry F.S., Xu X., Bangad V., Mensa F., Zou J., Xie X., Hu Y., Lu C., et al. Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals &#x2265;12 Years Old: A Phase 2/3 Trial. Vaccines. 2024;12:118. doi: 10.3390/vaccines12020118.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12020118</ArticleId><ArticleId IdType="pmc">PMC10893482</ArticleId><ArticleId IdType="pubmed">38400102</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C.H., Hansen C.H., Moustsen-Helms I.R., Moustsen-Helms I.R., Rasmussen M., Rasmussen M., S&#xf8;borg B., S&#xf8;borg B., Ullum H., Ullum H., et al. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: A national cohort study. Lancet Infect. Dis. 2024;24:e73&#x2013;e74. doi: 10.1016/S1473-3099(23)00746-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00746-6</ArticleId><ArticleId IdType="pubmed">38190834</ArticleId></ArticleIdList></Reference><Reference><Citation>van Werkhoven C.H., Valk A.-W., Smagge B., de Melker H.E., Knol M.J., Hahn&#xe9; S.J., Hof S.v.D., de Gier B. Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023. Eurosurveillance. 2024;29:2300703. doi: 10.2807/1560-7917.ES.2024.29.1.2300703.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2024.29.1.2300703</ArticleId><ArticleId IdType="pmc">PMC10905658</ArticleId><ArticleId IdType="pubmed">38179623</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha N.K., Burke P.C., Nowacki A.S., Gordon S.M. Effectiveness of the 2023&#x2013;2024 Formulation of the Coronavirus Disease 2019 Messenger RNA Vaccine. Clin. Infect. Dis. 2024:ciae132. doi: 10.1093/cid/ciae132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae132</ArticleId><ArticleId IdType="pubmed">38465901</ArticleId></ArticleIdList></Reference><Reference><Citation>Link-Gelles R., Ciesla A.A., Mak J., Miller J.D., Silk B.J., Lambrou A.S., Paden C.R., Shirk P., Britton A., Smith Z.R., et al. Early Estimates of Updated 2023&#x2013;2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults&#x2014;Increasing Community Access to Testing Program, United States, September 2023&#x2013;January 2024. MMWR. Morb. Mortal. Wkly. Rep. 2024;73:77&#x2013;83. doi: 10.15585/mmwr.mm7304a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7304a2</ArticleId><ArticleId IdType="pmc">PMC10843065</ArticleId><ArticleId IdType="pubmed">38300853</ArticleId></ArticleIdList></Reference><Reference><Citation>Witberg G., Barda N., Hoss S., Richter I., Wiessman M., Aviv Y., Grinberg T., Auster O., Dagan N., Balicer R.D., et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N. Engl. J. Med. 2021;385:2132&#x2013;2139. doi: 10.1056/NEJMoa2110737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110737</ArticleId><ArticleId IdType="pmc">PMC8531986</ArticleId><ArticleId IdType="pubmed">34614329</ArticleId></ArticleIdList></Reference><Reference><Citation>Comirnaty COVID-19 Vaccine  [Online] Summary of Product Characteristics. European Medicines Agency. 2022.  [(accessed on 21 July 2024)].  Available online:  https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf.</Citation></Reference><Reference><Citation>Goddard K., Lewis N., Fireman B., Weintraub E., Shimabukuro T., Zerbo O., Boyce T.G., Oster M.E., Hanson K.E., Donahue J.G., et al. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022;40:5153&#x2013;5159. doi: 10.1016/j.vaccine.2022.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.07.007</ArticleId><ArticleId IdType="pmc">PMC9273527</ArticleId><ArticleId IdType="pubmed">35902278</ArticleId></ArticleIdList></Reference><Reference><Citation>Husby A., Gulseth H.L., Hovi P., Hansen J.V., Pihlstr&#xf6;m N., Gunnes N., H&#xe4;rk&#xe4;nen T., Dahl J., Karlstad &#xd8;., Heli&#xf6; T., et al. Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: Population based cohort study. BMJ Med. 2023;2:e000373. doi: 10.1136/bmjmed-2022-000373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2022-000373</ArticleId><ArticleId IdType="pmc">PMC9978676</ArticleId><ArticleId IdType="pubmed">36936260</ArticleId></ArticleIdList></Reference><Reference><Citation>Fronza M., Thavendiranathan P., Chan V., Karur G.R., Udell J.A., Wald R.M., Hong R., Hanneman K. Myocardial Injury Pattern at MRI in COVID-19 Vaccine&#x2013;Associated Myocarditis. Radiology. 2022;304:553&#x2013;562. doi: 10.1148/radiol.212559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiol.212559</ArticleId><ArticleId IdType="pmc">PMC8856022</ArticleId><ArticleId IdType="pubmed">35166587</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  [Online] Selected Adverse Events Reported after COVID-19 Vaccination.  [(accessed on 21 July 2024)];2023  Available online:  https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html.</Citation></Reference><Reference><Citation>Smadja D.M., Yue Q.-Y., Chocron R., Sanchez O., Louet A.L.-L. Vaccination against COVID-19: Insight from arterial and venous thrombosis occurrence using data from VigiBase. Eur. Respir. J. 2021;58:2100956. doi: 10.1183/13993003.00956-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00956-2021</ArticleId><ArticleId IdType="pmc">PMC8051185</ArticleId><ArticleId IdType="pubmed">33863748</ArticleId></ArticleIdList></Reference><Reference><Citation>Elalamy I., Gerotziafas G., Alamowitch S., Laroche J.-P., Van Dreden P., Ageno W., Beyer-Westendorf J., Cohen A.T., Jimenez D., Brenner B., et al. SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia. Thromb. Haemost. 2021;121:982&#x2013;991. doi: 10.1055/a-1499-0119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1499-0119</ArticleId><ArticleId IdType="pmc">PMC8322589</ArticleId><ArticleId IdType="pubmed">33946120</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan B.E., Shen J.Y., Lim X.R., Tu T.M., Chang C.C.R., Khin H.S.W., Koh J.S., Rao J.P., Lau S.L., Tan G.B., et al. Cerebral venous thrombosis post BNT162b2 mRNA SARS-CoV-2 vaccination: A black swan event. Am. J. Hematol. 2021;96:E357&#x2013;E361. doi: 10.1002/ajh.26272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26272</ArticleId><ArticleId IdType="pmc">PMC8420211</ArticleId><ArticleId IdType="pubmed">34133027</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteley W.N., Ip S., Cooper J.A., Bolton T., Keene S., Walker V., Denholm R., Akbari A., Omigie E., Hollings S., et al. Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England. PLoS Med. 2022;19:e1003926. doi: 10.1371/journal.pmed.1003926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003926</ArticleId><ArticleId IdType="pmc">PMC8863280</ArticleId><ArticleId IdType="pubmed">35192597</ArticleId></ArticleIdList></Reference><Reference><Citation>Cari L., Fiore P., Alhosseini M.N., Sava G., Nocentini G. Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: An analysis of European data. J. Autoimmun. 2021;122:102685. doi: 10.1016/j.jaut.2021.102685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2021.102685</ArticleId><ArticleId IdType="pmc">PMC8220408</ArticleId><ArticleId IdType="pubmed">34174723</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekulovski M., Mileva N., Vasilev G.V., Miteva D., Gulinac M., Peshevska-Sekulovska M., Chervenkov L., Batselova H., Vasilev G.H., Tomov L., et al. Blood Coagulation and Thrombotic Disorders following SARS-CoV-2 Infection and COVID-19 Vaccination. Biomedicines. 2023;11:2813. doi: 10.3390/biomedicines11102813.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11102813</ArticleId><ArticleId IdType="pmc">PMC10604891</ArticleId><ArticleId IdType="pubmed">37893186</ArticleId></ArticleIdList></Reference><Reference><Citation>Grupper A., Rabinowich L., Schwartz D., Schwartz I.F., Ben-Yehoyada M., Shashar M., Katchman E., Halperin T., Turner D., Goykhman Y., et al. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus. Arab. Archaeol. Epigr. 2021;21:2719&#x2013;2726. doi: 10.1111/ajt.16615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ajt.16615</ArticleId><ArticleId IdType="pmc">PMC8250589</ArticleId><ArticleId IdType="pubmed">33866672</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyarsky B.J., Ou M.T.B., Greenberg R.S.B., Teles A.T.B., Werbel W.A., Avery R.K., Massie A.B., Segev D.L., Garonzik-Wang J.M. Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients. Transplantation. 2021;105:e56&#x2013;e57. doi: 10.1097/TP.0000000000003654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000003654</ArticleId><ArticleId IdType="pmc">PMC8084895</ArticleId><ArticleId IdType="pubmed">33560728</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahav G., Lustig Y., Lavee J., Benjamini O., Magen H., Hod T., Shem-Tov N., Shmueli E.S., Merkel D., Ben-Ari Z., et al. BNT162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study. eClinicalMedicine. 2021;41:101158. doi: 10.1016/j.eclinm.2021.101158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101158</ArticleId><ArticleId IdType="pmc">PMC8520708</ArticleId><ArticleId IdType="pubmed">34693234</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinelli S., Pascucci D., Laurenti P. Humoral response after a fourth dose of SARS-CoV-2 vaccine in immunocompromised patients. Results of a systematic review. Front. Public Health. 2023;11:1108546. doi: 10.3389/fpubh.2023.1108546.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1108546</ArticleId><ArticleId IdType="pmc">PMC10076800</ArticleId><ArticleId IdType="pubmed">37033069</ArticleId></ArticleIdList></Reference><Reference><Citation>Novavax  Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine [Online] 2021.  [(accessed on 6 July 2024)].  Available online:  https://ir.novavax.com/press-releases/2021-12-17-Novavax-and-Serum-Institute-of-India-Announce-World-Health-Organization-Grants-Emergency-Use-Listing-for-NVX-CoV2373-COVID-19-Vaccine.</Citation></Reference><Reference><Citation>Fix J., Mast T.C., Smith K., Baker N. Benefit&#x2013;risk assessment for the Novavax COVID-19 vaccine (NVX-CoV2373) Vaccine. 2024;42:2161&#x2013;2165. doi: 10.1016/j.vaccine.2024.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2024.03.036</ArticleId><ArticleId IdType="pubmed">38494410</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel N., Trost J.F., Guebre-Xabier M., Zhou H., Norton J., Jiang D., Cai Z., Zhu M., Marchese A.M., Greene A.M., et al. XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants. Sci. Rep. 2023;13:19176. doi: 10.1038/s41598-023-46025-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-46025-y</ArticleId><ArticleId IdType="pmc">PMC10628164</ArticleId><ArticleId IdType="pubmed">37932354</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration  Novavax COVID-19 Vaccine, Adjuvanted [Online]  [(accessed on 6 July 2024)];2023  Available online:  https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/novavax-covid-19-vaccine-adjuvanted#additional.</Citation></Reference><Reference><Citation>World Health Organization  Background Document on the Novavax NVX-CoV2373 Vaccine against COVID-19 [Online] 2021.  [(accessed on 6 July 2024)].  Available online:  https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Novavax-NVX-CoV2373-background.</Citation></Reference><Reference><Citation>Novavax  Novavax Submits Application to U.S. FDA for Updated Protein-Based 2024&#x2013;2025 Formula COVID-19 Vaccine [Online] 2024.  [(accessed on 6 July 2024)].  Available online:  https://ir.novavax.com/press-releases/2024-06-14-Novavax-Submits-Application-to-U-S-FDA-for-Updated-Protein-based-2024-2025-Formula-COVID-19-Vaccine.</Citation></Reference><Reference><Citation>Hotez P.J., Bottazzi M.E. Whole inactivated virus and protein-based COVID-19 vaccines. Annu. Rev. Med. 2022;73:55&#x2013;64. doi: 10.1146/annurev-med-042420-113212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-042420-113212</ArticleId><ArticleId IdType="pubmed">34637324</ArticleId></ArticleIdList></Reference><Reference><Citation>Reimer J.M., Karlsson K.H., L&#xf6;vgren-Bengtsson K., Magnusson S.E., Fuentes A., Stertman L. Matrix-M&#x2122; adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS ONE. 2012;7:e41451. doi: 10.1371/journal.pone.0041451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0041451</ArticleId><ArticleId IdType="pmc">PMC3402407</ArticleId><ArticleId IdType="pubmed">22844480</ArticleId></ArticleIdList></Reference><Reference><Citation>Stertman L., Palm A.K., Zarnegar B., Carow B., Lunderius Andersson C., Magnusson S.E., Carnrot C., Shinde V., Smith G., Glenn G., et al. The Matrix-M&#x2122; adjuvant: A critical component of vaccines for the 21st century. Hum. Vaccines Immunother. 2023;19:2189885. doi: 10.1080/21645515.2023.2189885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2189885</ArticleId><ArticleId IdType="pmc">PMC10158541</ArticleId><ArticleId IdType="pubmed">37113023</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath P.T., Galiza E.P., Baxter D.N., Boffito M., Browne D., Burns F., Chadwick D.R., Clark R., Cosgrove C., Galloway J., et al. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N. Engl. J. Med. 2021;385:1172&#x2013;1183. doi: 10.1056/NEJMoa2107659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107659</ArticleId><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc1;&#xf1;ez G., Dunkle L.M., Gay C.L., Kotloff K.L., Adelglass J.M., Essink B., Campbell J.D., Cloney-Clark S., Zhu M., Plested J.S., et al. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial. JAMA Netw. Open. 2023;6:e239135. doi: 10.1001/jamanetworkopen.2023.9135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.9135</ArticleId><ArticleId IdType="pmc">PMC10536880</ArticleId><ArticleId IdType="pubmed">37099299</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad S., Yuson C., Le A., Hissaria P. Myopericarditis following both BNT162b2 and NVX-CoV2373. Allergy Asthma Clin. Immunol. 2022;18:109. doi: 10.1186/s13223-022-00750-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13223-022-00750-7</ArticleId><ArticleId IdType="pmc">PMC9786414</ArticleId><ArticleId IdType="pubmed">36564782</ArticleId></ArticleIdList></Reference><Reference><Citation>Romanson B. Notes from the Field: Safety Monitoring of Novavax COVID-19 Vaccine among Persons Aged &#x2265; 12 Years&#x2014;United States, 13 July 2022&#x2013;13 March 2023. MMWR. Morb. Mortal. Wkly. Rep. 2023;72:850&#x2013;851. doi: 10.15585/mmwr.mm7231a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7231a4</ArticleId><ArticleId IdType="pmc">PMC10414997</ArticleId><ArticleId IdType="pubmed">37535499</ArticleId></ArticleIdList></Reference><Reference><Citation>Clothier H.J., Parker C., Mallard J.H., Effler P., Bloomfield L., Carcione D., Buttery J.P. Real-world Nuvaxovid COVID-19 vaccine safety profile after first 100,000 doses in Australia, 2022&#x2013;2023. medRxiv. 2024 doi: 10.1101/2024.03.17.24304409.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.03.17.24304409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunjimi O.B., Tsalamandris G., Paladini A., Varrassi G., Zis P. Guillain-Barr&#xe9; Syndrome Induced by Vaccination Against COVID-19: A Systematic Review and Meta-Analysis. Cureus. 2023;15:e37578. doi: 10.7759/cureus.37578.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.37578</ArticleId><ArticleId IdType="pmc">PMC10183219</ArticleId><ArticleId IdType="pubmed">37193456</ArticleId></ArticleIdList></Reference><Reference><Citation>Song J.-W., Hu W., Shen L., Wang F.-S. Safety and immunogenicity of COVID-19 vaccination in immunocompromised patients. Chin. Med. J. 2022;135:2656&#x2013;2666. doi: 10.1097/CM9.0000000000002505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CM9.0000000000002505</ArticleId><ArticleId IdType="pmc">PMC9945070</ArticleId><ArticleId IdType="pubmed">36719354</ArticleId></ArticleIdList></Reference><Reference><Citation>HMA-EMA Catalogues of Real-World Data Sources and Studies  Safety Profile of the NVX-CoV2373 Vaccine in Individuals &#x2265; 12 Years of Age in the United States [Online]. HMA-EMA Catalogues of Real-World Data Sources and Studies. 2024.  [(accessed on 21 July 2024)].  Available online:  https://catalogues.ema.europa.eu/node/3713/methodological-aspects.</Citation></Reference><Reference><Citation>Health Canada  Novavax Nuvaxovid COVID-19 Vaccine [Online] 2024.  [(accessed on 6 July 2024)].  Available online:  https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treatments/vaccines/novavax.html.</Citation></Reference><Reference><Citation>Mallory R.M., Formica N., Pfeiffer S., Wilkinson B., Marcheschi A., Albert G., McFall H., Robinson M., Plested J.S., Zhu M., et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A secondary analysis of a randomised, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 2022;22:1565&#x2013;1576. doi: 10.1016/S1473-3099(22)00420-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00420-0</ArticleId><ArticleId IdType="pmc">PMC9365313</ArticleId><ArticleId IdType="pubmed">35963274</ArticleId></ArticleIdList></Reference><Reference><Citation>Munro A.P.S., Janani L., Cornelius V., Aley P.K., Babbage G., Baxter D., Bula M., Cathie K., Chatterjee K., Dodd K., et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): A blinded, multicentre, randomised, controlled, phase 2 trial. Lancet. 2021;398:2258&#x2013;2276. doi: 10.1016/S0140-6736(21)02717-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02717-3</ArticleId><ArticleId IdType="pmc">PMC8639161</ArticleId><ArticleId IdType="pubmed">34863358</ArticleId></ArticleIdList></Reference><Reference><Citation>Raiser F., Davis M., Adelglass J., Cai M.R., Chau G., Cloney-Clark S., Eickhoff M., Kalkeri R., McKnight I., Plested J., et al. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults. Vaccine. 2023;41:5965&#x2013;5973. doi: 10.1016/j.vaccine.2023.07.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.07.056</ArticleId><ArticleId IdType="pubmed">37652823</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutikova L., Brash J.T., Helme K., Brewster J., Brand M., Adam A., Seager S., Kostev K., Schelling J. Characteristics and Outcomes for Recipients of NVX-CoV2373: A Real-World Retrospective Study in Germany. Vaccines. 2024;12:387. doi: 10.3390/vaccines12040387.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines12040387</ArticleId><ArticleId IdType="pmc">PMC11054037</ArticleId><ArticleId IdType="pubmed">38675769</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateo-Urdiales A., Sacco C., Petrone D., Bella A., Riccardo F., Del Manso M., Bressi M., Siddu A., Brusaferro S., Palamara A.T., et al. Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19. JAMA Netw. Open. 2023;6:e2336854. doi: 10.1001/jamanetworkopen.2023.36854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.36854</ArticleId><ArticleId IdType="pmc">PMC10551773</ArticleId><ArticleId IdType="pubmed">37792377</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwak E., Choe S.A., Bolormaa E., Choe Y.J., Wang C., Fix J., Vadivale M., Rousculp M.D. Short-Term Relative Effectiveness of Homologous NVX-CoV2373 and BNT162b2 COVID-19 Vaccinations in South Korea. medRxiv. 2024 doi: 10.1101/2024.07.02.24309830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.07.02.24309830</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Stepien S., Qian J., Gidding H., Nicolopoulos K., Amin J., Cheng A., Macartney K. Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection. Vaccine. 2023;41:5587&#x2013;5591. doi: 10.1016/j.vaccine.2023.07.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.07.050</ArticleId><ArticleId IdType="pubmed">37524631</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee E.S.M., Choe Y.J., Choe S.A., Gwak E.S., Kwon D.D. Relative Effectiveness of the NVX-CoV2373 Vaccine Compared with the BNT162b2 Vaccine in Adolescents. Pediatr. Infect. Dis. J. 2024 doi: 10.1097/INF.0000000000004463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000004463</ArticleId><ArticleId IdType="pubmed">38985994</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Updated (2023&#x2013;24 Formula) Novavax COVID-19 Vaccine [Online]  [(accessed on 29 June 2024)];2024  Available online:  https://www.cdc.gov/vaccines/covid-19/info-by-product/novavax/downloads/novavax-standing-orders.pdf.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. (COVID-19) [Online]  [(accessed on 6 July 2024)];2024  Available online:  https://clinicaltrials.gov/study/NCT05975060?intr=NVX-CoV2601&amp;rank=3.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines (COVID-19) [Online]  [(accessed on 6 July 2024)];2024  Available online:  https://clinicaltrials.gov/study/NCT05973006?intr=NVX-CoV2601&amp;rank=2.</Citation></Reference><Reference><Citation>ClinicalTrials.gov  Phase 2/3 Heterologous Boosting Study with Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines (COVID-19) [Online]  [(accessed on 6 July 2024)];2024  Available online:  https://clinicaltrials.gov/study/NCT05925127?intr=NVX-CoV2601&amp;rank=1.</Citation></Reference><Reference><Citation>Singh A.V., Kayal A., Malik A., Maharjan R.S., Dietrich P., Thissen A., Siewert K., Curato C., Pande K., Prahlad D., et al. Interfacial Water in the SARS Spike Protein: Investigating the Interaction with Human ACE2 Receptor and In Vitro Uptake in A549 Cells. Langmuir. 2022;38:7976&#x2013;7988. doi: 10.1021/acs.langmuir.2c00671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.langmuir.2c00671</ArticleId><ArticleId IdType="pubmed">35736838</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>